BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Print selected from Online session15/07/2002

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded
NEWS 22	Jul 02	FOREGE no longer contains STANDARDS file segment

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

Print selected from Online session15/07/2002

FILE 'HOME' ENTERED AT 16:55:35 ON 15 JUL 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:55:43 ON 15 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 14 JUL 2002 HIGHEST RN 438526-30-8
DICTIONARY FILE UPDATES: 14 JUL 2002 HIGHEST RN 438526-30-8

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10042203bayer25a.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:56:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     36 TO ITERATE

100.0% PROCESSED      36 ITERATIONS                                 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          361 TO     1079
PROJECTED ANSWERS:              44 TO      476

L2            13 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:56:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    825 TO ITERATE

100.0% PROCESSED     825 ITERATIONS                                 365 ANSWERS
SEARCH TIME: 00.00.02

L3           365 SEA SSS FUL L1

=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   140.28     140.49

FILE 'USPATFULL' ENTERED AT 16:56:20 ON 15 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:56:20 ON 15 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
L4            17 L3

=> d abs bib fhitstr 1-17

L4   ANSWER 1 OF 17  USPATFULL
AB     This invention relates to the use of a group of heteroaryl ureas
       containing nitrogen in treating p38 mediated diseases, and
       pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2002:126779  USPATFULL
TI     Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase
       inhibitors
IN     Dumas, Jacques, Orange, CT, UNITED STATES
       Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
       Khire, Uday, Hamden, CT, UNITED STATES
       Sibley, Robert N., North Haven, CT, UNITED STATES
       Hatoum-Mokdad, Holia, Hamden, CT, UNITED STATES
       Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
       Gunn, David E., Hamden, CT, UNITED STATES
       Lowinger, Timotthy B., Nishinomiya City, JAPAN
       Scott, William J., Guilford, CT, UNITED STATES
```

Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
PA BAYER CORPORATION (U.S. corporation)
PI US 2002065296 A1 20020530
AI US 2001-838286 A1 20010420 (9)
RLI Continuation-in-part of Ser. No. US 2001-778039, filed on 7 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1999-425229, filed on 22 Oct 1999, PENDING Continuation of Ser. No. US 1999-257265, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-54-7P**, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(1,3-dioxoisoindolin-5-yloxy)phenyl]urea
(prepn. of heteroaryl ureas contg. nitrogen hetero-atoms as p38 kinase inhibitors)
RN 284461-54-7 USPATFULL
CN Urea, N-[4-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)oxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:78859 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES

Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)
PI US 2002042517 A1 20020411
AI US 2001-948915 A1 20010910 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 17 USPATFULL
AB Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:218507 USPATFULL
TI Allosteric inhibitors of pyruvate kinase
IN Abraham, Donald J., Midlothian, VA, United States
Wang, Changging, Richmond, CA, United States
Danso-Danquah, Richmond, Richmond, VA, United States
Burnett, James C., Ashland, VA, United States
Joshi, Gajanan S., Glen Allen, VA, United States
Hoffman, Steven J., Carlisle, MA, United States
PI US 2001046997 A1 20011129
AI US 2001-799873 A1 20010307 (9)
RLI Continuation-in-part of Ser. No. US 1998-46643, filed on 24 Mar 1998, GRANTED, Pat. No. US 6214879

DT Utility
FS APPLICATION
LREP McGuire Woods, LLP, Suite 1800, 1750 Tysons Boulevard, Tysons Corner, McLean, VA, 22102
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **289060-07-7**
(pyruvate kinase allosteric inhibitors for therapeutic use)
RN 289060-07-7 USPATFULL
CN 1,3-Benzenedicarboxylic acid, 5-[4-(methoxycarbonyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001034447 A1 20011025
AI US 2001-773604 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility

FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:171152 USPATFULL
TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States
PI US 2001027202 A1 20011004
AI US 2001-773658 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Arlington Courthouse Plaza I, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:139616 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001016659 A1 20010823
AI US 2001-773672 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL

CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino] carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 17 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:123628 USPATFULL

TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States

PI US 2001011136 A1 20010802

AI US 2001-773675 A1 20010202 (9)

RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon Blvd., Arlington, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **284461-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-42-3 USPATFULL

CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino] carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:123627 USPATFULL
TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011135 A1 20010802
AI US 2001-773659 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse Plaza 1, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284**461-42-3P
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 17 USPATFULL

AB The present invention relates to novel quinoline derivatives and quinazoline derivatives represented by the following formula (I): ##STR1## [wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.4 -alkyl, or R.sub.1 and R.sub.2 together form C.sub.1 -C.sub.3 -alkylene, X is O, S or CH.sub.2, W is CH or N, and Q is a substituted aryl group or substituted heteroaryl group] and their pharmaceutically acceptable salts, having platelet-derived growth factor receptor autophosphorylation inhibitory activity, to pharmaceutical compositions containing these compounds, and to methods for the treatment of diseases associated with abnormal cell growth such as tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:150184 USPATFULL

TI Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same

IN Kubo, Kazuo, Takasaki, Japan
Ohyama, Shinichi, Takasaki, Japan
Shimizu, Toshiyuki, Takasaki, Japan
Nishitoba, Tsuyoshi, Takasaki, Japan
Kato, Shinichiro, Takasaki, Japan
Murooka, Hideko, Takasaki, Japan
Kobayashi, Yoshiko, Takasaki, Japan

PA Kirin Beer Kabushiki Kaisha, Tokyo-to, Japan (non-U.S. corporation)

PI US 6143764 20001107
WO 9717329 19970515

AI US 1998-68660 19980506 (9)
WO 1996-JP3229 19961105
19980506 PCT 371 date
19980506 PCT 102(e) date

PRAI JP 1995-313555 19951107
JP 1996-62121 19960223

DT Utility

FS Granted

EXNAM Primary Examiner: Seaman, D. Margaret

LREP Foley & Lardner

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **190**727-78-7P
(prepn. of quinoline and quinazoline derivs. inhibiting platelet-derived growth factor receptor autophosphorylation)

RN 190727-78-7 USPATFULL

CN Urea, N-[2,5-bis(trifluoromethyl)phenyl]-N'-[4-[(6,7-dimethoxy-4-

quinolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 17 USPATFULL

AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:67289 USPATFULL

TI Anti-inflammatory compounds

IN Dixon, James Scott, Malvern, PA, United States
Hall, Ralph Floyd, Villanova, PA, United States
Marshall, Lisa Ann, Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth Judik, Wayne, PA, United States
Winkler, James David, Fort Washington, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

PI US 5912270 19990615
WO 9533712 19951214

AI US 1996-737650 19961122 (8)
WO 1995-US6677 19950602
19961122 PCT 371 date
19961122 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-252716, filed on 2 Jun 1994, now patented, Pat. No. US 5470882

DT Utility

FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Dinner, Dara L., Venetianer, Stephen, Kinzig, Charles
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **447-64-3P**
(prepn. of antiinflammatory ureidophenoxybenzenesulfonates)
RN 447-64-3 USPATFULL
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 17 USPATFULL
AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:105872 USPATFULL
TI Anti-inflammatory compounds
IN Dixon, James S., Malvern, PA, United States
Hall, Raplh F., Villanova, PA, United States
Marshall, Lisa A., Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth J., Wayne, PA, United States
Winkler, James D., Fort Washington, PA, United States
PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)
PI US 5470882 19951128
AI US 1994-252716 19940602 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Conrad, III, Joseph M.
LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.

CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **447-64-3**
(anti-inflammatory benzenesulfonic acid derivs., their prepn., and their activity)
RN 447-64-3 USPATFULL
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 17 USPATFULL
AB This invention relates to the novel compounds and pharmaceutical compositions of Formula (I).

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:80325 USPATFULL
TI Anti-inflammatory compounds
IN Adams, Jerry L., Wayne, PA, United States
Hall, Ralph F., Villanova, PA, United States
Seibel, George L., Wayne, PA, United States
PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)
PI US 5447957 19950905
AI US 1994-252851 19940602 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Barts, Samuel
LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **171103-10-9P**
(antiinflammatory (ureidophenoxy)benzoic acids and derivs. as

inhibitors of phospholipase A2 and CoA-independent transacylase)
RN 17 103-10-9 USPATFULL
CN Benzoic acid, 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 17 USPATFULL
AB Insecticidal and acaricidal novel substituted furazans of the formula ##STR1## n which R.sup.1 and R.sup.2 are identical or different and represent hydrogen, halogen, alkyl, alkoxy, alkylthio, halogenoalkyl, halogenoalkoxy, halogenoalkylthio or optionally substituted aryloxy, or

R.sup.1 and R.sup.2 together represent an optionally substituted alkylene radical which is interrupted by 1 or 2 oxygen atoms or is bonded to the phenyl radical via 1 or 2 oxygen atoms,

R.sup.3 and R.sup.4 are identical or different and represent hydrogen, halogen, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy,

R.sup.5 represents optionally substituted cycloalkyl, and

X represents oxygen or sulphur.

Intermediates of the formula ##STR2## in which B is --NH.sub.2, --NO.sub.2 or --NCX,

R.sup.3 and R.sup.4 are identical or different and represent hydrogen, halogen, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy,

R.sup.6 represents 2,2-difluoro-1-methylcycloprop-1-yl or the ##STR3## radical, Y represents hydrogen, methyl, fluorine or chlorine, and

Y.sup.1 and Y.sup.2 are identical or different and represent fluorine or chlorine,

are also new.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 99:63034 USPATFULL
TI Substituted furazans and insecticidal and acaricidal use
IN Girrenberg, Wilhelm, Sprockhovel, Germany, Federal Republic of
Harhold, Albrecht, Leverkusen, Germany, Federal Republic of
Steffens, Robert, Cologne, Germany, Federal Republic of
PA Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

PI US 4853397 19890801
AI US 1987-66920 19870625 (7)
PRAI DE 1986-3622862 19860708
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Sprung Horn Kramer & Woods
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,8
DRWN No Drawings
LN.CNT 574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 113664-71-4P
(prepn. of, as insecticide and acaricide)
RN 113664-71-4 USPATFULL
CN Urea, N-[4-(2-chloro-2,3,3-trifluorocyclobutyl)-3-(trifluoromethyl)phenyl]-N'-[4-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1,2,5-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 17 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component which is a selected carbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 85:38961 USPATFULL
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P., Greenfield, IN, United States
Clinton, Albert J., Indianapolis, IN, United States
PI US 4526997 19850702
AI US 1984-611780 19840518 (6)
RLI Division of Ser. No. US 1981-260962, filed on 6 May 1981, now patented, Pat. No. US 4468380 which is a continuation of Ser. No. US 1979-107304,

Filed on 26 Dec 1979, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Warren, Charles F.; Assistant Examiner: Picard, R. A.
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 2063-69-6
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 17 USPATFULL
AB 1,3,5-Triazinones of the formula ##STR1## where R.sup.1, R.sup.2 and R.sup.3 have the meanings given in the description, are used for controlling undesirable plant growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 85:23703 USPATFULL
TI 1,3,5-Triazinones and their use for controlling undesirable plant growth
IN Parg, Adolf, Bad Durkheim, Germany, Federal Republic of
Hamprecht, Gerhard, Weinheim, Germany, Federal Republic of
Muerzer, Bruno, Otterstadt, Germany, Federal Republic of
PA BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)
PI US 4512797 19850423
AI US 1983-462024 19830128 (6)
RLI Continuation-in-part of Ser. No. US 1982-446064, filed on 1 Dec 1982, now abandoned
PRAI DE 1981-3147879 19811203
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Keil & Weinkauf
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,8
DRWN No Drawings
LN.CNT 800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 86507-45-6
(cyclocondensation of, with acyl isocyanates)
RN 86507-45-6 USPATFULL
CN Urea, N-[5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 17 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component which is a selected carbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 84:48395 USPATFULL
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P., Greenfield, IN, United States
Clinton, Albert J., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 4468380 19840828
AI US 1981-260962 19810506 (6)
RLI Continuation of Ser. No. US 1979-107304, filed on 26 Dec 1979, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 52
ECL Exemplary Claim: 1,27
DRWN No Drawings
LN.CNT 1366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 2063-69-6
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 17 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second

component selected from nicarbazin and 4,4'-dinitrocarbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 80:40562 USPATFULL
TI Anticoccidial combinations comprising nicarbazin and the polyether antibiotics
IN Callender, Maurice E., Indianapolis, IN, United States
Jeffers, Thomas K., Greenfield, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 4218438 19800819
AI US 1979-12165 19790214 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LI.CNT 352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 2063-69-6
(anticoccidial compn. contg. polyether antibiotic and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



Print selected from Online session15/07/2002

=>
Uploading 10042203bayer25a.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,I

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:56:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0 PROCESSED 36 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 361 TO 1079
PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:56:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 825 TO ITERATE

100.0% PROCESSED 825 ITERATIONS 365 ANSWERS
SEARCH TIME: 00.00.02

L3 365 SEA SSS FUL L1

=> file uspatall

Print selected from Online session15/07/2002

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.28	140.49

FILE 'USPATFULL' ENTERED AT 16:56:20 ON 15 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:56:20 ON 15 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 3
L4 17 L3

=> d .bs bib fhitstr 1-17

L4 ANSWER 1 OF 17 USPATFULL
AB This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:126779 USPATFULL
TI Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
IN Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Khire, Uday, Hamden, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
Hatoum-Mokdad, Holia, Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Gunn, David E., Hamden, CT, UNITED STATES
Lowinger, Timotthy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
PA BAYER CORPORATION (U.S. corporation)
PI US 2002065296 A1 20020530
AI US 2001-838286 A1 20010420 (9)
RLI Continuation-in-part of Ser. No. US 2001-778039, filed on 7 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1999-425229, filed on 22 Oct 1999, PENDING Continuation of Ser. No. US 1999-257265, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 284461-54-7P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(1,3-dioxoisoindolin-5-yloxy)phenyl]urea
(prepn. of heteroaryl ureas contg. nitrogen hetero-atoms as p38 kinase inhibitors)
RN 284461-54-7 USPATFULL
CN Urea, N-[4-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)oxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:78859 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)
PI US 2002042517 A1 20020411
AI US 2001-948915 A1 20010910 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CN 3675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 284461-42-3P
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 17 USPATFULL
AB Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:218507 USPATFULL
TI Allosteric inhibitors of pyruvate kinase
IN Abraham, Donald J., Midlothian, VA, United States
Wang, Changging, Richmond, CA, United States
Danso-Danquah, Richmond, Richmond, VA, United States
Burnett, James C., Ashland, VA, United States
Joshi, Gajanan S., Glen Allen, VA, United States
Hoffman, Steven J., Carlisle, MA, United States
PI US 2001046997 A1 20011129
AI US 2001-799873 A1 20010307 (9)
RLI Continuation-in-part of Ser. No. US 1998-46643, filed on 24 Mar 1998, GRANTED, Pat. No. US 6214879
DT Utility
FS APPLICATION
LREP McGuire Woods, LLP, Suite 1800, 1750 Tysons Boulevard, Tysons Corner, McLean, VA, 22102
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 289060-07-7
(pyruvate kinase allosteric inhibitors for therapeutic use)
RN 289060-07-7 USPATFULL
CN 1,3-Benzenedicarboxylic acid, 5-[4-(methoxycarbonyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001034447 A1 20011025
AI US 2001-773604 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284161-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284161-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 17 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:171152 USPATFULL
TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States
PI US 2001027202 A1 20011004
AI US 2001-773658 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Arlington Courthouse Plaza I, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 284461-42-3P
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-42-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)

Applicants



L4 ANSWER 6 OF 17 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:139616 USPATFULL

TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States

PI US 2001016659 A1 20010823

AI US 2001-773672 A1 20010202 (9)

RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **284461-42-3P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-42-3 USPATFULL

CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 17 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:123628 USPATFULL

TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States

PI US 2001011136 A1 20010802

AI US 2001-773675 A1 20010202 (9)

RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon Blvd., Arlington, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 284461-42-3P
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-42-3 USPATFULL

CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 17 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:123627 USPATFULL

TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States

PI US 2001011135 A1 20010802

AI US 2001-773659 A1 20010202 (9)

RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse Plaza 1, Arlington, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3686

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 284461-42-3P
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-42-3 USPATFULL

CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 17 USPATFULL

AB The present invention relates to novel quinoline derivatives and quinazoline derivatives represented by the following formula (I): ##STR1## [wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.4 -alkyl, or R.sub.1 and R.sub.2 together form C.sub.1 -C.sub.3 -alkylene, X is O, S or CH.sub.2, W is CH or N, and Q is a substituted aryl group or substituted heteroaryl group] and their pharmaceutically acceptable salts, having platelet-derived growth factor receptor autophosphorylation inhibitory activity, to pharmaceutical compositions containing these compounds, and to methods for the treatment of diseases associated with abnormal cell growth such as tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:150184 USPATFULL

TI Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same

IN Kubo, Kazuo, Takasaki, Japan
Ohyama, Shinichi, Takasaki, Japan
Shimizu, Toshiyuki, Takasaki, Japan
Nishitoba, Tsuyoshi, Takasaki, Japan
Kato, Shinichiro, Takasaki, Japan
Murooka, Hideko, Takasaki, Japan
Kobayashi, Yoshiko, Takasaki, Japan

PA Kirin Beer Kabushiki Kaisha, Tokyo-to, Japan (non-U.S. corporation)

PI US 6143764 20001107
WO 9717329 19970515

AI US 1998-68660 19980506 (9)
WO 1996-JP3229 19961105
19980506 PCT 371 date
19980506 PCT 102(e) date

PRAI JP 1995-313555 19951107
JP 1996-62121 19960223

DT Utility

FS Granted

EXNAM Primary Examiner: Seaman, D. Margaret

LREP Foley & Lardner

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 190727-78-7P
(prepn. of quinoline and quinazoline derivs. inhibiting platelet-derived growth factor receptor autophosphorylation)

RN 190727-78-7 USPATFULL

CN Urea, N-[2,5-bis(trifluoromethyl)phenyl]-N'-[4-[(6,7-dimethoxy-4-

q:inolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 17 USPATFULL

AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:67289 USPATFULL

TI Anti-inflammatory compounds

IN Dixon, James Scott, Malvern, PA, United States
Hall, Ralph Floyd, Villanova, PA, United States
Marshall, Lisa Ann, Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth Judik, Wayne, PA, United States
Winkler, James David, Fort Washington, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

PI US 5912270 19990615
WO 9533712 19951214

AI US 1996-737650 19961122 (8)
WO 1995-US6677 19950602
19961122 PCT 371 date
19961122 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-252716, filed on 2 Jun 1994, now patented, Pat. No. US 5470882

DT Utility

FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Dinner, Dara L., Venetianer, Stephen, Kinzig, Charles
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **447-64-3P**
(prepn. of antiinflammatory ureidophenoxybenzenesulfonates)
RN 447-64-3 USPATFULL
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 17 USPATFULL
AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:105872 USPATFULL
TI Anti-inflammatory compounds
IN Dixon, James S., Malvern, PA, United States
Hall, Raplh F., Villanova, PA, United States
Marshall, Lisa A., Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth J., Wayne, PA, United States
Winkler, James D., Fort Washington, PA, United States
PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)
PI US 5470882 19951128
AI US 1994-252716 19940602 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Conrad, III, Joseph M.
LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.

CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **447-64-3**
(anti-inflammatory benzenesulfonic acid derivs., their prepn., and their activity)
RN 447-64-3 USPATFULL
CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 17 USPATFULL
AB This invention relates to the novel compounds and pharmaceutical compositions of Formula (I).

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:80325 USPATFULL
TI Anti-inflammatory compounds
IN Adams, Jerry L., Wayne, PA, United States
Hall, Ralph F., Villanova, PA, United States
Seibel, George L., Wayne, PA, United States
PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)
PI US 5447957 19950905
AI US 1994-252851 19940602 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Barts, Samuel
LREP Donner, Dara L., Venetianer, Stephen, Lentz, Edward T.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **171103-10-9P**
(antiinflammatory (ureidophenoxy)benzoic acids and derivs. as

...hibitors of phospholipase A2 and CoA-independent transacylase)
RN 171103-10-9 USPATFULL
CN Benzoic acid, 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L... ANSWER 13 OF 17 USPATFULL
AB Insecticidal and acaricidal novel substituted furazans of the formula ##STR1## n which R.sup.1 and R.sup.2 are identical or different and represent hydrogen, halogen, alkyl, alkoxy, alkylthio, halogenoalkyl, halogenoalkoxy, halogenoalkylthio or optionally substituted aryloxy, or

R.sup.1 and R.sup.2 together represent an optionally substituted alkylene radical which is interrupted by 1 or 2 oxygen atoms or is bonded to the phenyl radical via 1 or 2 oxygen atoms,

R.sup.3 and R.sup.4 are identical or different and represent hydrogen, halogen, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy,

R.sup.5 represents optionally substituted cycloalkyl, and

X represents oxygen or sulphur.

Intermediates of the formula ##STR2## in which B is --NH.sub.2, --NO.sub.2 or --NCX,

R.sup.3 and R.sup.4 are identical or different and represent hydrogen, halogen, alkyl, alkoxy, halogenoalkyl or halogenoalkoxy,

R.sup.6 represents 2,2-difluoro-1-methylcycloprop-1-yl or the ##STR3## radical, Y represents hydrogen, methyl, fluorine or chlorine, and

Y.sup.1 and Y.sup.2 are identical or different and represent fluorine or chlorine,

are also new.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 89:63034 USPATFULL
TI Substituted furazans and insecticidal and acaricidal use
IN Sirrenberg, Wilhelm, Sprockhovel, Germany, Federal Republic of
Mauchold, Albrecht, Leverkusen, Germany, Federal Republic of
Steffens, Robert, Cologne, Germany, Federal Republic of
PA Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

PI US 4853397 19890801
AI US 1987-66920 19870625 (7)
PRAI DE 1986-3622862 19860708
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Sprung Horn Kramer & Woods
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,8
DRWN No Drawings
LN.CNT 874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **113664-71-4P**
(prepn. of, as insecticide and acaricide)
RN 113664-71-4 USPATFULL
CN Urea, N-[4-(2-chloro-2,3,3-trifluorocyclobutyl)-3-(trifluoromethyl)phenyl]-N'-[4-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1,2,5-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



L ANSWER 14 OF 17 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component which is a selected carbanilide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 85:38961 USPATFULL
TI Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P., Greenfield, IN, United States
Clinton, Albert J., Indianapolis, IN, United States
PI US 4526997 19850702
AI US 1984-611780 19840518 (6)
RLI Division of Ser. No. US 1981-260962, filed on 6 May 1981, now patented, Pat. No. US 4468380 which is a continuation of Ser. No. US 1979-107304,

filed on 26 Dec 1979, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Warren, Charles F.; Assistant Examiner: Picard, R. A.
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LIN.CNT 884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 2063-69-6
(anticoccidal compns. contg. polyether antibiotics and)
RN 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 17 USPATFULL
AB 1,3,5-Triazinones of the formula ##STR1## where R.sup.1, R.sup.2 and R.sup.3 have the meanings given in the description, are used for controlling undesirable plant growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 85:23703 USPATFULL
TI 1,3,5-Triazinones and their use for controlling undesirable plant growth
IN Parg, Adolf, Bad Durkheim, Germany, Federal Republic of
Hamprecht, Gerhard, Weinheim, Germany, Federal Republic of
Wuerzer, Bruno, Otterstadt, Germany, Federal Republic of
PA BASF Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)
PI US 4512797 19850423
AI US 1983-462024 19830128 (6)
RLI Continuation-in-part of Ser. No. US 1982-446064, filed on 1 Dec 1982, now abandoned
PRAI DE 1981-3147879 19811203
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Keil & Weinkauf
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,8
DRWN No Drawings
LIN.CNT 800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 86607-45-6
(cyclocondensation of, with acyl isocyanates)
RN 86607-45-6 USPATFULL
CN Urea, N-[5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrophenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L ANSWER 16 OF 17 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second component which is a selected carbanilide.

C S INDEXING IS AVAILABLE FOR THIS PATENT.
A 84:48395 USPATFULL
T Anticoccidial combinations comprising polyether antibiotics and carbanilides
IN O'Doherty, George O. P., Greenfield, IN, United States
Clinton, Albert J., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 4468380 19840828
AI US 1981-260962 19810506 (6)
RLI Continuation of Ser. No. US 1979-107304, filed on 26 Dec 1979, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Page, Kathleen R. S., Whale, Arthur R.
CLMN Number of Claims: 52
ECL Exemplary Claim: 1,27
DRWN No Drawings
LN.CNT 3366
C S IND EXING IS AVAILABLE FOR THIS PATENT.
IT 2063-69-6
(anticoccidal compns. contg. polyether antibiotics and)
PT 2063-69-6 USPATFULL
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



L ANSWER 17 OF 17 USPATFULL
AB The present invention is directed to novel anticoccidial compositions and methods of employing the same to control coccidiosis in poultry. These compositions comprise a polyether antibiotic and a second

P int s lected from Online session15/07/2002

...mponent selected from nicarbazin and 4,4'-dinitrocarbanilide.

C S INDEXING IS AVAILABLE FOR THIS PATENT.
A ...:40562 USPATFULL
T ...ticoccidial combinations comprising nicarbazin and the polyether a tibiotics
I ...C llender, Maurice E., Indianapolis, IN, United States
...effers, Thomas K., Greenfield, IN, United States
P ...Eli Lilly and Company, Indianapolis, IN, United States (U.S. ...rporation)
P ...S 4218438 19800819
A ...S 1979-12165 19790214 (6)
D ...tility
F ...anted
E NAM Primary Examiner: Rosen, Sam
L EP ...ge, Kathleen R. S., Whale, Arthur R.
C MN Number of Claims: 33
E L Exemplary Claim: 1
D WN No Drawings
I .CNT 2
C S INDEXING IS AVAILABLE FOR THIS PATENT.
I 2067-69-6
...(anticoccidial compn. contg. polyether antibiotic and)
P 2067-69-6 USPATFULL
C Ur..., N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(4-chlorophenoxy)phenyl]-...CI) (CA INDEX NAME)

C



=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	102.91	243.40

FILE 'CAPLUS' ENTERED AT 16:58:08 ON 15 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

P int selected from Online session17:01Page 18

FILE COVERS 1907 - 15 Jul 2002 VOL 137 ISS 3
FILE LAST UPDATED: 14 Jul 2002 (20020714/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

= d h s

FILE 'HOME' ENTERED AT 16:55:35 ON 15 JUL 2002)

FILE 'REGISTRY' ENTERED AT 16:55:43 ON 15 JUL 2002
L STRUCTURE UPLOADED
L 13 S L1
L 365 S L1 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 16:56:20 ON 15 JUL 2002
L 17 S L3

FILE 'CAPLUS' ENTERED AT 16:58:08 ON 15 JUL 2002

= s l3
L 32 L3

= d abs bib fhitstr 1-32

L ANSWER 1 OF 32 CAPLUS COPYRIGHT 2002 ACS
G



I



II

A The title compds. [I; E = (un)substituted aryl, heteroaryl; A = aryl,

heteroaryl, heterocyclyl; X = S, O, SO2, SO, CH2, CHOH, CO; Z = O, S; p = 0-1; q = 0-1; D = CH, T = CR8, M = C and Q = NT7p, wherein p = 0 and q = 1; or D = CH, T = CR8, M = C and Q = NR7p, wherein p =1 and q = 0, or D = CH, T = CR8, M = C and Q = S or O, wherein q = 0; or D = N, T = CR8, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = N, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = CR8, M = N and Q = CH, wherein q = 0; R1 = alkyl, haloalkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = alkylene or alkylene substituted by oxo, and is linked together with N atom to which it is attached and to one of the benzimidazole N atoms to form a heterocyclic compd. fused to the benzimidazole; R7 = H, alkyl, etc.; R8 = H, halo] and their salts, useful in the treatment of hyperproliferative diseases, were prepd. Thus, reacting Me [5-(4-aminophenoxy)-1H-benzimidazol-2-yl]carbamate (prepn. given) with 3-chlorophenyl isocyanate in THF afforded 69% II which showed pIC50 of > 7.0 in TIE-2 and VEGFR2 enzyme assays.

A 2002:428885 CAPLUS
D 137:6179
T Preparation of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors
I Cheung, Mui; Harris, Philip Anthony; Hasegawa, Masaichi; Ida, Satoru; Kano, Kazuya; Nishigaki, Naohiko; Sato, Hideyuki; Veal, James Martin; Washio, Yoshiaki; West, Rob I.
PA Glaxo Group Limited, UK; Glaxosmithkline K.K.
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
D Patent
L English
F N.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
P WO 2002044156	A2	20020606	WO 2001-US44553	20011128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

P RI US 2000-253868P P 20001129
US 2001-310939P P 20010808
OS MARPAT 137:6179
I **433224-24-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)
P 433224-24-9 CAPLUS
C Urea, N-[4-[(2-amino-1H-benzimidazol-5-yl)oxy]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L ANSWER 2 OF 32 CAPLUS COPYRIGHT 2002 ACS
G



I



II

A Title compds. I [n = 1-2 forming a central 5-6 membered (un)satd. carbocyclic ring; m = 0-3; [CH2]mY is attached to said central carbocyclic ring at position 2, 3, or 4; X, Y = carboxamide, thiocarboxamide, ureido, aminosulfonyl, etc.] were prepd. Examples include over 30 compds. synthesized, assays for rotamase inhibition, neuronal cell growth/regeneration, in-vivo protective effects in an animal model of stroke/myocardial infarction (rat) and an in-vivo model of hair growth (mouse). For instance, 3-nitroaniline was reacted with 4-methylphenylsulfonylsulfonyl chloride and 4-methoxyphenylsulfonyl chloride (DMA, Et3N) to give the bis(sulfonamide) as a solid. This intermediate was reduced (EtOHaq, NH4Cl, In.degree., reflux, 4 h) and subsequently treated with 3,5-dichlorophenylisocyanate to give II. II had IC50 = 162 nM for rotamase (a measure of cyclophilin (CyP) A binding). I have an affinity for CyP-type immunophilin proteins and are useful for the

treatment of neurol. disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.

AN 2002:428855 CAPLUS
DN 137:20228
TI Sulfonamido/amido/ureido-phenyl-amides as cyclophilin binding compounds
IN Hamilton, Gregory S.; Belyakov, Sergei; Waal, Mark; Wei, Ling; Wu, Yong-Qian; Steiner, Joseph P.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002044126	A2	20020606	WO 2001-US44449	20011128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-253074P P 20001128
US 2001-291966P P 20010521
OS MARPAT 137:20228
IT 1395-43-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; prepn. of 1,3-disubstituted sulfonamido/amido/ureido-Ph-amides as immunophilin ligands)
RN 1395-43-3 CAPLUS
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2002 ACS
AB This invention relates to the use of a group of heteroaryl ureas (I; for example, N-(2-methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea) contg. N in treating p38 mediated diseases, and pharmaceutical compns. for use in such therapy. I is A NHC(O)NH-B or a pharmaceutically acceptable salt thereof, wherein A is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group, B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 50 C atoms with a cyclic structure bound directly to N, contg. at least 5 cyclic members with 0-4 members of groups consisting of

N, O and S. Information about the substituents for A and B are given in the claims. Although the methods of prepn. are not claimed, 37 example prepns. are included as well as examples of prepn. of intermediates. No pharmacol. data is included.

AN 2002:409267 CAPLUS
DN 137:6098
TI Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.; Natoum-Mokdad, Holia; Monahan, Mary-katherine; Gunn, David E.; Lowinger, Timotthy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U. S. Ser. No. 778,039.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002065296	A1	20020530	US 2001-838286	20010420
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	B1	19990225		
	US 1999-425229	A2	19991022		
	US 2001-778039	A2	20010207		

OS MARPAT 137:6098
IT 284461-54-7P, N-[2-Methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(1,3-dioxoisoindolin-5-yloxy)phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl ureas contg. nitrogen hetero-atoms as p38 kinase inhibitors)
RN 284461-54-7 CAPLUS
CN Urea, N-[4-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)oxy]phenyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2002 ACS
AB Chem. structures have been identified which allosterically modify pyruvate kinase and inhibit enzymic activity. These compds. can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, e.g. the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying Hb's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease. Prepn. of e.g. 2-phenylethyloxy-5-formylbenzoic acid is described.

AN 2001:869018 CAPLUS
DN 136:700
TI Allosteric inhibitors of pyruvate kinase for therapeutic use
IN Abraham, Donald J.; Wang, Changging; Dan [illegible]-Danquah, Richmond; Burnett, James C.; Joshi, Gajanan S.; Hoffman, Steven J.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. 6,214,879.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001046997	A1	20011129	US 2001-799873	20010307
	US 6214879	B1	20010410	US 1998-46643	19980324
PRAI	US 1998-46643	A2	19980324		

IT 289060-07-7
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyruvate kinase allosteric inhibitors for therapeutic use)
RN 289060-07-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[4-(methoxycarbonyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, dimethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2002
GI



I

AB Malarial parasites rely on aspartic prot[illegible]es called plasmepsins to digest Hb during the intraerythrocytic stage. [illegible]asmepsins from Plasmodium falciparum and Plasmodium vivax have be[illegible] cloned and expressed for a variety of structural and enzymic studi[illegible] Recombinant plasmepsins possess kinetic similarity to the nativ[illegible]nzymes, indicating their suitability for target-based antimalari[illegible]drug development. We developed an automated assay of P. falciparum pla[illegible]psin II and P. vivax plasmepsin to quickly screen compds. in the Walter [illegible]d chem. database. A low-mol.-mass (346 Da) diphenylurea der[illegible] [WR268961 (I)] was found to inhibit plasmepsins with a Ki of 1 to 6 [illegible].M. This compd. appears to be selective for plasmepsin, since it is a [illegible]or inhibitor of the human aspartic protease cathepsin D (Ki greate[illegible]han 280 .mu.M). I inhibited the growth of P. falciparum strains W2 a[illegible] D6, with 50% inhibitory concns. ranging from 0.03 to 0.16 .mu.g/mL, but [illegible]s much less toxic to mammalian cells. The Walter Reed chem. database [illegible]tains over 1,500 compds. with a diphenylurea core structure, 9 of which [illegible]bit the plasmepsins, with Ki values ranging from 0.05 to 0.68 .mu.M. [illegible]ese nine compds. show specificity for the plasmepsins over hu[illegible] cathepsin D, but they are poor inhibitors of P. falciparum growth i[illegible]. Computational docking expts. indicate how diphenylurea compds. bind [illegible]he plasmepsin active site and inhibit the enzyme.

AN [illegible]001:623551 CAPLUS

DN 135:327005

TI New class of small nonpeptidyl compound[illegible]ocks Plasmodium falciparum development in vitro by inhibiting plas[illegible]sins

AU Jiang, Suping; Prigge, Sean T.; Wei, La[illegible]ao, Yu-E.; Hudson, Thomas H.; Gerena, Lucia; Dame, John B.; Kyle, Der[illegible] E.

CS Department of Parasitology, Division of [illegible]perimental Therapeutics, Walter Reed Army Institute of Research, Silve[illegible]ring, MD, 20910-7500, USA

SO Antimicrobial Agents and Chemotherapy [illegible], 45(9), 2577-2584
CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

IT 447-79-0, WR 100081
RL: BAC (Biological activity or effecto[illegible]except adverse); BSU (Biological study, unclassified); THU (Therapeutic [illegible]: BIOL (Biological study); USES (Uses)
(new class of small nonpeptidyl compo[illegible]blocks Plasmodium falciparum development in vitro by inhibitin[illegible]epsins)

RN 447-79-0 CAPLUS

CN Benzenesulfonic acid, 5-chloro-2-[[[[3-c[illegible]ro-4-(4-chlorophenoxy)phenyl]amino]carbonyl]ami[illegible]4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT [illegible]0 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 32 CAPLUS COPYRIGHT 20[illegible] ACS
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - [illegible]ILABLE VIA OFFLINE PRINT *

AB Title compds. [I; X = O, S; A = 1,4-C6H[illegible] 1,3-C6H4, 1,7-naphthyl; L = H, 2,6-(CH3)2, 2-(CH3)3C, 6-(CH3)3C; R1 = [illegible]NHCO, CH3CH2NHCO, (CH3)3CNHCO, CH3(CH2)5NHCO, CF3NHCO, C6H5NHCO, 2-CH3C6H4NHCO, 3-CH3C6H4NHCO, 4-CH3C6H4NHCO, 2,6-(CH3)2C6H3NHCO, 4-CF[illegible]C6H4NHCO, 2,3-F2C6H4NHCO; q = 0-8; m = 0-8; n = 0-8] and pharmacol. acc[illegible]ble salts, which are useful as therapeutic and/or preventive agents [illegible] diabetes, hyperlipemia, arteriosclerosis, cancers, are prepd. [illegible], the title compd. II was prepd.

AN 2000:742094 CAPLUS
DN 133:296435
TI Preparation of amine derivatives useful [illegible]ents for diabetes, hyperlipemia, arteriosclerosis, and cancer
IN Fujita, Takashi; Wada, Kunio; Oguchi, M[illegible]oru; Honma, Hidehito; Fujiwara, Toshihiko
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061581	A1	20001019	WO 2000-JP2216	20000406
	W: AU, BR, CA, CN, CZ, HU, ID, [illegible], N, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, [illegible]R, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2000351779	A2	20001219	JP 2000-104702	20000406
	EP 1167366	A1	20020102	EP 2000-915362	20000406
	R: AT, BE, CH, DE, DK, ES, FR, GB, [illegible] IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 2000009594	A	20020604	BR 2000-9594	20000406
	NO 2001004847	A	20011207	NO 2001-4847	20011005
PRAI	JP 1999-99981	A	19990407		
	WO 2000-JP2216	W	20000406		

OS MARPAT 133:296435
IT 301548-73-2P
RL: BAC (Biological activity or effe[illegible]xcept adverse); BSU (Biological study, unclassified); SPN (Synthetic p[illegible]ration); THU (Therapeutic use); BIOL (Biological study); PREP (Prepa at[illegible]; USES (Uses)
(prepn. of amine derivs. as useful a[illegible]s for diabetes, hyperlipemia, arteriosclerosis, and cancer)
RN 301548-73-2 CAPLUS
CN Urea, N-[3-[[2-[[4-[(2,4-dioxo-5-thiaz[illegible]nyl)methyl]phenoxy]methyl]-1-methyl-1H-benzimidazol-6-yl]oxy]phen[illegible][3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Print selected from Online session15/07/2 ...

PAGE 1-A



PAGE 1-B



RE.CNT 16 THERE ARE 16 CITED REFERENC ... LABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN ... FORMAT

L5 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2002 ...
GI



AB This invention relates to the prepn. a... e of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6 m... red (hetero)aryl, esp. Ph or pyridinyl; M = bridging group; L1 = ... o'aryl with at least one (un)substituted sulfamoyl, carboxy, ... bamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tri... aryl or heteroaryl groups] for the treatment of raf mediated diseases, ...ch as cancer (no data). Approx. 100 invention compds. and numerous inte... diates were prepd. For instance, 3-tert-butylaniline was coupl... with bis(trichloromethyl)carbonate to form t... socyanate, followed by addn. of 4-(3-N-methylcarbamoylphenoxy)aniline ... n. given) to afford the urea II.

AN 2000:493516 CAPLUS

DN 133:120157

TI Preparation of .omega.-carboxy(hetero... ...bstituted diphenyl ureas as raf kinase inhibitors

IN Ried..., Bernd; Dumas, Jacques; Khire, ... Lovinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill ... Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Pe... N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

Print selected from Online session17:01Pa...

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000042012	A1	20000720	00-US648	20000112
W: AE, AL, AM, AT, AU, AZ, BA, BB			BR, BY, CA, CH, CN, CR, CU,	
CZ, DE, DK, DM, EE, ES, FI, GB			GD, GH, GM, HR, HU, ID, IL,	
IN, IS, JP, KE, KG, KP, KR, KZ			LC, LR, LS, LT, LU, LV, MA,	
MD, MG, MK, MN, MW, MX, NO, NZ			PL, PT, RO, RU, SD, SE, SG, SI,	
SK, SL, TJ, TM, TR, TT, TZ, UA			US, UZ, VN, YU, ZA, ZW, AM,	
AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ			, UG, ZW, AT, BE, CH, CY, DE,	
DK, ES, FI, FR, GB, GR, IE, IT			, MC, NL, PT, SE, BF, BJ, CF,	
CG, CI, CM, GA, GN, GW, ML, MR,			SN, TD, TG	
EP 1140840	A1	20011010	00-903239	20000112
R: AT, BE, CH, DE, DK, ES, FR, GB			IT, LI, LU, NL, SE, MC, PT,	
IE, SI, LT, LV, FI, RO				
US 2001011135	A1	20010802	773659	20010202
US 2001011136	A1	20010802	773675	20010202
US 2001016659	A1	20010823	01-773672	20010202
US 2001027202	A1	20011004	01 773658	20010202
US 2001034447	A1	20011025	01-773604	20010202
JP 2001003463	A	20010912	01-3463	20010712
US 2002042517	A1	20020411	01-948915	20010910
PRAI US 1999-115877P	P	19990113		
US 1999-257266	A2	19990225		
US 1999-425228	A2	19991022		
WO 2000-US648	W	20000112		

OS MARPAT 133:120157
IT 284461-42-3P
PL: BAC (Biological activity or effect, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological activity); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting aryl isocyanates with arylamines)
RN 284461-42-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methyl-4-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2002
GI

Print selected from Online session15/07/2



AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q wh = 5-6 membered cyclic structure; L1 = substituted cyclic m et ng at least 5 members; M = bridging group having al least one a m 3; each of L and L1 contains 0-4 members of the group co i q of N, O and S); B = (un)substituted up to tricyclic aryl aryl moiety of up to 30 carbon atoms with at least one 6-mem structure bound directly to D contg. 0-4 members of the group co f N, O and S], useful in treating p38 mediated diseases, were p g., a multi-step synthesis of the urea II which showed IC50 of against p38, was given. Compds. I are effective at 0.01-200 oral administration).

AN 2000:493376 CAPLUS

DN 133:120155

TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, U. W.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, J. Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley,

PA Bayer Corporation, USA

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041698	A1	20000720	WO US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, B , CZ, DE, DK, DM, EE, ES, FI, G , IN, IS, JP, KE, KG, KP, KR, K , MD, MG, MK, MN, MW, MX, NO, N , SK, SL, TJ, TM, TR, TT, TZ, U , AZ, BY, KG, KZ, MD, RU, TJ, T			BY, CA, CH, CN, CR, CU, GD, GH, GM, HR, HU, ID, IL, I , LR, LS, LT, LU, LV, MA, P , RO, RU, SD, SE, SG, SI, U UZ, VN, YU, ZA, ZW, AM,	
	RW: GH, GM, KE, LS, MW, SD, SL, , DK, ES, FI, FR, GB, GR, IE, , CG, CI, CM, GA, GN, GW, ML,			ZW, AT, BE, CH, CY, DE, NL, PT, SE, BF, BJ, CF, S TD, TG	
	EP 1158985	A1	20011205	EP 905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO			, LI, LU, NL, SE, MC, PT,	

PRAI US 1999-115878P P 19990113
US 1999-257265 A2 19990225
US 1999-425229 A2 19991022
WO 2000-US768 W 20000113

OS MARPAT 133:120155

IT 284461-86-5P
BAC (Biological activity or effe t adverse); BSU (Biological study, unclassified); RCT (Reactant) S y thetic preparation); THU (Therapeutic use); BIOL (Biological PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Print selected from Online session17:01Pa

Print selected from Online session15/07/[illegible]

(prepn. of .omega.-carboxy aryl s[illegible] di-Ph ureas as p38 kinase inhibitors)

RN [illegible]34461-86-5 CAPLUS

CN [illegible] Pyridinecarboxylic acid, 5-[4-[[[[(trifluoromethyl)phenyl]amino]carbon[illegible]henoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCE[illegible] FOR THIS RECORD
ALL CITATIONS AVAILABLE IN [illegible] MAT

L5 ANSWER 9 OF 32 CAPLUS COPYRIGHT 20[illegible]

GI







CO_2H II

AB Title compds. [I; wherein Y1 = a gro[illegible]nted by (un)substituted-Ph, (un)substituted-2-naphthyl; X1 is O, [illegible]O or S; A = CH, N] and stereoisomers are prepd. and tested [illegible]sts of IgE antibody, therefore useful as preventive or th[illegible]gents for allergic diseases and having cytotoxic activities use[illegible]umor agents. The title compd. II was prepd.

AN [illegible]000:84754 CAPLUS

DN 132:151571

TI Preparation of anthranilic acid deri[illegible] preventive or therapeutic agents

IN Tsuchiya, Naoki; Takeuchi, Susumu; [illegible]kumi; Hase, Naoki; Yamori, Takao; Tsuruo, Takashi

Print selected from Online session17:01[illegible]

PA Teijin Limited, Japan
SO PCT Int. Appl., 213 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	AP	N NO.	DATE
PI	WO 2000005198	A1	20000203	WO	3969	19990723
	W: AE, AL, AM, AT, AU, AZ, BA, , DE, DK, EE, ES, FI, GB, GD, , JP, KE, KG, KP, KR, KZ, LC, , MN, MW, MX, NO, NZ, PL, PT, , TM, TR, TT, UA, UG, US, UZ, , MD, RU, TJ, TM				BY, CA, CH, CN, CU, CZ, HR, HU, ID, IL, IN, IS, LT, LU, LV, MD, MG, MK, SE, SG, SI, SK, SL, TJ, ZW, AM, AZ, BY, KG, KZ,	
	RW: GH, GM, KE, LS, MW, SD, SL, , ES, FI, FR, GB, GR, IE, IT, , CI, CM, GA, GN, GW, ML, MR, ,				AT, BE, CH, CY, DE, DK, PT, SE, BF, BJ, CF, CG, TG	
	AU 9948004	A1	20000214	AU	9004	19990723
	EP 1101755	A1	20010523	EP	1522	19990723
	R: AT, BE, CH, DE, DK, ES, FR, , IE, SI, LT, LV, FI, RO				LI, LU, NL, SE, MC, PT,	
PRAI	JP 1998-209410	A	19980724			
	JP 1998-258486	A	19980911			
	JP 1998-369808	A	19981225			
	JP 1998-369809	A	19981225			
	WO 1999-JP3969	W	19990723			

OS MARPAT 132:151571
IT **257606-49-8P**
RL: SPN (Synthetic preparation); THU (Th c use); BIOL (Biological study); PREP (Preparation); USES (Us) (prepn. of anthranilic acid deriv. a nitive or therapeutic agents)
RN 257606-49-8 CAPLUS
CN Benzoic acid, 2-[[[4-[4-[[cis-4-[[[(t yl]amino]cyclohexyl]oxy]phenoxy]phen]a omethyl)phenyl]amino]carbon mino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





RE.CNT 5 THERE ARE 5 CITED REFERENCES AVA ... FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE R ...

L5 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2002 A

AB A method of treating a p-38 mediated dise ... er than cancer comprises administration of BNHCONHA [A = (substitu ... pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gt ... 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-te ... l-2-(3-tetrahydrofuranyloxy)aniline (prepn. give ... p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert ... 2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methyl ... urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu

AN 1999:421667 CAPLUS

DN 131:58659

TI Preparation of diaryl ureas as inhibitors ... 8 kinase.

IN Miller, Scott; Osterhout, Martin; Dumas, ... Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, Willi ... Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holi ... riguez, Mareli; Sibley, Robert; Wang, Ming

PA Bayer Corporation, USA

SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APP	... NO.	DATE
PI	WO 9932463	A1	19990701	WO	...7265	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, B				...CA, CH, CN, CU, CZ, DE,	
	DK, EE, ES, FI, GB, GD, GE, GH, G				...HU, ID, IL, IN, IS, JP,	
	KE, KG, KP, KR, KZ, LC, LK, LR, L				...LU, LV, MD, MG, MK, MN,	
	MW, MX, NO, NZ, PL, PT, RO, RU, S				...SG, SI, SK, SL, TJ, TM,	
	TR, TT, UA, UG, UZ, VN, YU, ZW, A				...BY, KG, KZ, MD, RU, TJ, TM	
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, Z				...BE, CH, CY, DE, DK, ES,	
	FI, FR, GB, GR, IE, IT, LU, MC, N				...SE, BF, BJ, CF, CG, CI,	
	CM, GA, GN, GW, ML, MR, NE, SN, T					
	CA 2315715	AA	19990701	CA	...5715	19981222
	AU 9919399	A1	19990712	AU	...99	19981222
	EP 1042305	A1	20001011	EP	...4221	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, G				...LI, LU, NL, SE, MC, PT,	
	IE, SI, LT, LV, FI, RO					
	JP 2001526276	T2	20011218	JP	...3400	19981222
PRAI	US 1997-995749	A	19971222			
	WO 1998-US27265	W	19981222			

OS MARPAT 131:58659

IT 228399-63-1P
BL: BAC (Biological activity or effector, ... adverse); BSU (Biological study, unclassified); SPN (Synthetic prep ... ; THU (Therapeutic use);

BIOL (Biological study); PREP (Preparatio FS (Uses)
(prepn. of diaryl ureas as inhibitors kinase)

RN 228399-63-1 CAPLUS

CN Urea, N-[2-methoxy-5-(trifluoromethyl)phe -[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX N



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVA A FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE R

L5 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2002 A
G



I



II

AB The invention relates to 1,3-disubstitute s I [R1 = (un)substituted aryl; R2 = NO2, NH2; X = O, S], and a met prepg. them by treating arom. amines with isocyanates. The isocy may be formed in situ, and the reaction carried out in a solvent suc oluene, at, e.g., 80.degree.C. If a nitro group is formed, ay be reduced with H2 in the presence of a Pd catalyst to give an amir up. The obtained 1,3-disubstituted ureas are inhibitors of he activity of the enzyme acyl co-enzyme A:cholesterol acyltransferase (A , and may be used to inhibit cholesterol esterification and absorption ercholesterolemia. For instance, reaction of 4-(4'-nitrophenoxy) with 2,5-difluorophenyl isocyanate gave 76% title compd. II. The at gave 49% inhibition of rat liver ACAT at 2 .mu.M, and 58% inhibi f ACAT in rabbit intestinal mucosa, at the same concn., both in vitro

AN 1999:421643 CAPLUS

DN 131:73441

TI 1,3-Disubstituted ureas useful as ACAT ir ors, and method for their preparation

IN Oremus, Vladimir; Smahovsky, Vendelin; Fa ra, Viera; Kakalik, Ivan;

Schmidtova, Ludmila; Zemanek, Marian
PA Slovako- Farma, A.S., Slovakia
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9932437	A1	19990701	WO K19	19981216
W: AL, AM, AT, AU, AZ, BA, BB, BG, B			CA, CH, CN, CU, CZ, DE,	
DK, EE, ES, FI, GB, GE, GH, GM, H			, ID, IL, IN, IS, JP, KE,	
KG, KP, KR, KZ, LC, LK, LR, LS, I			J, LV, MD, MG, MK, MN, MW,	
MX, NO, NZ, PL, PT, RO, RU, SD, S			G, SI, SK, SL, TJ, TM, TR,	
TT, UA, UG, US, UZ, VN, YU, ZW, A			, BY, KG, KZ, MD, RU, TJ, TM	
RW: GH, GM, KE, LS, MW, SD, SZ, UG, Z			, BE, CH, CY, DE, DK, ES,	
FI, FR, GB, GR, IE, IT, LU, MC, N			E, BF, BJ, CF, CG, CI,	
CM, GA, GN, GW, ML, MR, NE, SN, T				
AU 9916976	A1	19990712	AU 5976	19981216
EP 1042278	A1	20001011	EP 51715	19981216
R: AT, BE, CH, DE, DK, ES, FR, GB, G			LI, LU, NL, SE, PT, IE,	
SI, FI, RO				
JP 2001526259	T2	20011218	JP 525374	19981216
PRAI SK 1997-1751	A	19971219		
WO 1998-SK79	W	19981216		

OS MARPAT 131.73441
IT 223544-40-9P
RL: BAC (Biological activity or effector, adverse); BSU (Biological study, unclassified); SPN (Synthetic prep); THU (Therapeutic use); BIOL (Biological study); PREP (Preparatic US (Uses)
(prepn. of 1,3-disubstituted ureas as nhibitors)
RN 228544-40-9 CAPLUS
CN Urea, N-[4-(4-nitrophenoxy)phenyl]-N'-[3- ioromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVA E FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE F MAT

L5 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2002 A
GI



II

AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or [illegible]-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical [illegible] for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepd. For instance, reaction of tolyl isocyanate with 2-methoxy-5-trifluoromethanesulfonyl)aniline in EtOAc gave title compd. II. In an in vitro kinase assay, all compds. displayed IC50 values between 1 nM and 10 μM.

AN 1999:421642 CAPLUS

DN 131:58658

TI Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

IN Miller, Scott; Osterhout, Martin; Dumas, J[illegible]; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; W[illegible]ing

PA Bayer Corporation, USA

SO PCT Int. Appl., 89 pp.
CODEN: PIXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932436	A1	19990701	WO 1[illegible]6081	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD				
	CA 2315646	AA	19990701	CA 1[illegible]315646	19981222
	AU 9919054	A1	19990712	AU 1[illegible]9054	19981222
	EP 1049664	A1	20001108	EP 1[illegible]3809	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526258	T2	20011218	JP 2[illegible]25373	19981222
	BR 9814375	A	20020521	BR 9[illegible]4375	19981222
	NO 20000032[illegible]30	A	20000821	NO 2[illegible]230	20000621
PRAI	US 1997-990344	A	19971222		
	WO 1998-US26081	W	19981222		

OS MARPAT 131:58658

IT 228399-63-1P
BAC (Biological activity or effector, adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation ... USES (Uses)
(prepn. of sym. and unsym. substituted ... ureas with inhibitory
effects on tumors mediated by r... kinas...
RN 228399-63-... CAPLUS
CN Urea, N-[2-methoxy-5-(trifluorometh...phen... -4-(4-
methylphenoxy)phenyl]- (9CI) (CA INDEX N...



RE.CNT 3 THERE ARE 3 CITED REFERE... AVA... FOR THIS RECORD
AL... CITATIONS AVAILABLE IN THE RE... AT

L5 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2002 AC
AB Sodium 2-[2-[3-[4-chloro-3-(trifluoromethy...yl]ureido]-4-
(trifluoromethyl)phenoxy]-4,5-dichlorobenz...onate was prepd. in 5
steps from 3,4-dichlorophenol and 4-chloro...robenzotrifluoride. Also
prepd. were sodium 2-[2-[3-[3,5-bis(trifluo...yl)phenyl]ureido]-4-
(trifluoromethyl)phenoxy]-5-(1,1-dimethylp...benzenesulfonate and
sodium 2-[2-[3-[4-chloro-3-(trifluoromethy...l]ureido]-4-
(trifluoromethyl)phenoxy]-5-(1,1-dimethylp...benzenesulfonate. For ear
edema induced in the mouse by 12-O-tetrade...lphorbol 13-acetate at 50
mg/ear topically, 2-[2-[3-[4-chloro-3-(tri...omethyl)phenyl]ureido]-4-
(trifluoromethyl)phenoxy]-5-(1,1-dimethylp...)benzenesulfonic acid
exhibited an ID50 of 0.32 mg/ear and 2-[2-...
bis(trifluoromethyl)phenyl]amino]carbonyl]... 4-
(trifluoromethyl)phenoxy]-5-(1,1-dimethylp...benzenesulfonic acid
exhibited an ID50 of 0.87 mg/ear.
AN 1999:384011 CAPLUS
DN 131:44661
TI Anti-inflammatory compounds
IN Dixon, James Scott; Hall, Ralph Floyd; Ma... Lisa Ann; Chilton, Floyd
H., III; Mayer, Ruth Judik; Winkler, James...d
PA Smithkline Beecham Corporation, USA; The J... Hopkins University
SO U.S., 17 pp., Cont.-in-part of U.S. 5,470,...
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APP	ON NO.	DATE
PI	US 5912270	A	19990615	US ...	57650	19961122
	US 5470882	A	19951128	US ...	51716	19940602
	WO 9533712	A1	19951214	WO ...	US5677	19950602
	W: JP, US					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR...				T, LU, MC, NL, PT, SE	
PRAI	US 1994-252...		19940602			
	WO 1995-US6...		19950602			

OS MARPAT 131:44661
IT 447-64-3P
RL: BAC (Biological activity or effector,... adverse); BSU (Biological

Print selected fro Online session15/0

study, unclas ified); SPN (Synthe epa ; BIOL (Biological study); PREP Preparation)
(prepn. of antiinflammatory ureidophen nesulfonates)
RN 47-64-3 CAPLUS
CN Benzenesulfo c acid, 5-(1,1-dimeth rop -(trifluoromethyl)-2-[[[[3-(trifl romethyl)phenyl]amino rbo o]phenoxy]- (9CI) (CA INDEX NAME)



RE CN 28 THER ARE 28 CITED REFERENCE AV FOR THIS RECORD
ALL ITATIONS AVAILABLE IN T F

L5 ANSWER 14 OF 2 CAPLUS COPYRIGHT 2
GI



I II

AB The title comds. I [R1 and R2 repr s r C1-4 alkyl, or R1 and R2 together form C1 to C3 alkylene X s O, S or CH2; W represents CH or N; and represents substit stituted heteroaryl] are prepd. I inh bit platelet-derive receptor a tophosphory ation and are useful in the nt of cancer, arthritis, etc. The tit e compd. II (prepn. giv mg/kg i.p. once daily for days) incre sed the survival of m planted leukemic P388 cells by 130%
AN 1997:414195 APLUS
DN 127:34137
TI Preparation o quinoline and quinaz e ves inhibiting

Print selected fro Online session17: Fig 3

platelet-derived growth factor recept... ...sphorylation
IN Kubo, Kazuo; Ohyama, Shinichi; Shimizu, ... k ; Nishitoba, Tsuyoshi;
Kato, Shinichiro; Murooka, Hideko; Koba... ...hiko; et al.
PA Kirin Beer Kabushiki Kaisha, Japan; K... ; Ohyama, Shinichi;
Shimizu, Toshiyuki; Nishitoba, Tsuyosh... Shinichiro
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9717329	A1	19970515	WO ...P9229	19961105
W: AL, AM, AT, AU, AZ, BA, BB, B...			...A, CH, CN, CU, CZ, DE,	
DK, EE, ES, FI, GB, GE, HU, I...			...S, KG, KR, KZ, LC, LK,	
LR, LS, LT, LU, LV, MD, MG, MK...			...K, NO, NZ, PL, PT, RO,	
RU, SD, SE, SG, SI, SK, TJ, TM, TR...			...A, UG, US, UZ, VN, AM,	
AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH...			...K, ES, FI, FR, GB, GR,	
IE, IT, LU, MC, NL, PT, SE, BF, B...			...CG, CI, CM, GA, GN, ML,	
MR, NE, SN, TD, TG				
AU 9673400	A1	19970529	AU ...73400	19961105
EP 860433	A1	19980826	EP ...935541	19961105
R: CH, DE, FR, GB, LI				
US 6143764	A	20001107	US ...8 ...0	19980506
PRAI JP 1995-313559	A	19951107		
JP 1996-62121	A	19960223		
WO 1996-JP3229	W	19961105		

OS MARPAT 127:34 37
IT **190727-78-7P**
RL: BAC (Biological activity or effect... ...pt adverse); **BSU (Biological**
study, unclassified); SPN (Synthetic ... ...on); **THU (Therapeutic use);**
BIOL (Biological study); PREP (Preparat... ...SES (Uses)
(prepn. of quinoline and quinazoline ... ...hibiting
platelet-derived growth factor rece... ...phosphorylation)
RN 190727-78-7 CAPLUS
CN Urea, N-[2,5-bis(trifluoromethyl)phen... ...[...,7-dimethoxy-4-
quinolinyl)oxy]phenyl]- (9CI) (CA IN...



L5 ANSWER 15 OF CAPLUS COPYRIGHT 200

AB CoA-independe transacylase (CoA-IT) inhi s are disclosed for inhibiting or reducing cell prolifera on human or mammal. Compds. for inhibiting proliferation or indu g a osis exclude 1-O-octadecyl-2-O-methyl-sn-glycero-3 pho holine (I) or alkyl lysophospholipid analogs, but the I a s are disclosed for treatment of other CoA-IT-mediated dis n. of e.g. di-Et 1-(3,4,5-trip enyl-2-oxo-2,3-dihydroim y heptanephosphonate (II) is described. II inhibited CoA-IT at o 9 .mu.M; II also showed apoptosis-ind cing activity. The spec b ion of CoA-IT by I is also describe .

AN 1997:207756 CAPLUS

DI 126:195233

TI Compounds for inhibition of CoA-indep dent ansacylase, induction of apoptosis, treating CoA-independent trans se-dependent diseases, and inhibiting cell proliferation

IN Winkler, James David; Chilton, Floyd i

PA Smithkline Beecham Corporation, USA; W s' University; Winkler, James David; Chilton, Floyd Iii

SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPL	ION NO.	DATE
PI WO 9704765	A1	19970213	O	US 257	19960724
W: JP, U					
RW: AT, B CH, DE, DK, ES, FI, FR , IT, LU, MC, NL, PT, SE					
EP 841910	A1	19980520		501	19960724
R: BE, C , DE, ES, FR, GB, IT, LI					
JP 11511130	T2	19990928		752	19960724
PRAI US 1995-2239P	P	19950725			
WO 1996-US1225	W	19960724			

P int selected fro nline session15/ 7/ 0

IT 173730-67-1P
-L: BAC (Biol gical activity or effect , e ot adverse); BSU (Biological
tudy, unclass fied); SPN (Synthetic p pa n): THU (Therapeutic use);
BIOL (Biologic l study); PREP (Prepar ion) ES (Uses)
(compds. for inhibition of CoA-ind ende transacylase, induction of
apoptosis, treating CoA-indepenon tra lase-dependent diseases and
inhibiting cell proliferation, and omp ep .)
RN 173730-67-1 CAPLUS
CN Benzenesulfonic acid, 4,5-dichloro-2- -[[hloro-3-
(trifluoromet)phenyl]amino]carbony amin - rifluoromethyl)phenoxy]-
, monosodium salt (9CI) (CA INDEX NAM)



L5 NSWER 16 OF 3 CAPLUS COPYRIGHT 20 ACS
AB T-18-O-CH3 (1)-octadecyl-2-O-methyl n-gl ro-3-phosphocholine) is an
antiproliferative agent, blocking the rowt f cancer cells both in vitro
and in vivo. owever, there is contr ersy garding the mechanism
leading to its antiproliferative effe s. -independent transacylase
(CoA-IT) is an enzyme that remodels a chic te between specific
phospholipid donor and acceptor mols. n a iet of mammalian cells.
ET-18-O-CH3 was a potent inhibitor of oA-1 C5 , 0.5 .mu.M), and
kinetic anal. revealed that its inhib ion competitive with the
lyso-phospholipid substrate. The goal of t current study was to explore
the connection between inhibition of A-IT d antiproliferative effects
using several structurally distinct i ibit of CoA-IT. ET-18-O-CH3 and
other inhibitors of CoA-IT were found o in it cell proliferation and
thymidine incorporation into the DNA, s we as to induce apoptosis in
human HL-60 monocytic leukemia cells. The hanism of apoptosis induced
by ET-18-O-CH3 appeared to be differe fr hat induced by tumor
necrosis factor; the former failed to cti NF .kappa.B, whereas tumor
necrosis factor did. Closer examn. o the rmacol. of apoptosis in this
model revealed that compds. that were truc al related to CoA-IT
inhibitors, but lacked CoA-IT inhibito y ac it , also failed to induce
apoptosis. In addn., compds. that inh bite ther enzymes that
participate in arachidonic acid metab cyc oxygenase, 5-lipoxygenase and
phospholipase A2, did not induc apop sis. aken together, these results
demonstrate that inhibition of A IT an inked to blockade of
proliferation and the induction of ap tosi n HL-60 cells.
AN 1990:702444 CAPLUS

Print selected rom nline session1 :01Page 10

Print selected from online session15, 7/20

DN 126:166148
TI Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells
AU Winkler, James D.; Eris, Tamer; Sung, hiu ; Chabot-Fletcher, Marie; Mayer, Ruth J.; Surette, Marc E.; Chi on, yd .
CS Dep. Immunopharmacol. Med. Chem., Smit Klin eec am Pharmaceuticals, King of Prussia, PA, USA
SO Journal of Pharmacology and Experimental Th peutics (1996), 279(2), 956-966
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English
IT 162793-63-7, Skf 45905
RL: BAC (Biological activity or effector, pt verse); BSU (Biological study, unclassified); BIOL (Biological stu (inhibitors of CoA-independent transacyl ase induce apoptosis in human HL-60 cells)
RN 162793-62-7 CAPLUS
CN Benzenesulfonic acid, 4,5-dichloro-2-[[[[3-chloro-4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L ANSWER 17 O 32 CAPLUS COPYRIGHT 0 AC
G



I

AB The invention relates to the nov[illegible] ds. [illegible] pharmaceutical compns. of I [R1 = SO3H, S(O)n-C1-4 alkyl; n = 0-2; R2 ha[illegible], (substituted) C1-8 alkyl, C1-8 alkoxy; m = 1, 2; P = C(O)R7, (O)R7; R4, R8, R9 = H, C1-4 alkyl; R5 = H, halo, CF3, Me, (CH2)tC(O)2R8 CH2OH; t = 0-2; R6 = H, halo; R7 = (substituted) aryl, substituted aryl C1-2 alkyl, (substituted C1-8 alkyl, NR9R10 (substituted) aryl, (substituted) aryl-C1-2 alkyl, (substituted) C1-8 alkyl, R9NR10 form 5- to 7-membered (un)satd. ring with optional addnl. hetero atom of O/N or S; X = O, S; with provisions] and pharmaceutically acceptable salts thereof. The invention also relates to a method of treating a re[illegible]ng inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amt. of a compd. or compn. of I. Prep. of selected compds. of the invention is described. Compds. of the invention demonstrated phospholipase A2 inhibition, generally at [illegible]mM levels.

AN 1996:137693 CAPLUS

DN 124:165248

TI Aryl antiinflammatory compounds, their preparation, and their activity

IN Adams, Jerry Leroy; Hall, Ralph Floyd

PA SmithKline Beecham Corp., USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPL. NO.	DATE
PI	WO 9533458	A1	19951214	WO 1995-US6951	19950602
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-252[illegible]8		19940602		
OS	MARPAT 124:[illegible]52[illegible]8				

IT 174083-25-1P

BL (Biological activity or effect, [illegible]pt [illegible]erse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aryl antiinflammatory compds., prepn. and activity)

RN 174083-25-1 CAPLUS

CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-4-[(trifluoromethyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L5 ANSWER 18 O 32 CAPLUS COPYR HT 20(A
GI



I II

AB Pharmaceutical compns. are disclosed w ntain I (R1 = Cl; R2 = H, Cl, R3 = Cl, CF3; R4 = Ph substitut d at 1 tions with Cl or CF3; when R1 and R2 are both Cl, then R3 = CF3) or II = Cl, C((CH3)2)CH2CH3; R2 = H, Cl, Me; R1 = H, Cl; R3 = Cl, CF3; R4 = with Cl or CF3, or disubstituted Ph su st substituted at 1-2 positions ed once by Cl or CF3 and once by 3-chlorophenoxy or 4-chlorophenoxy; wi visions] and a pharmaceutically acceptable diluent or r. Also disclosed is a method for treating or reducing inflam in a mammal by administering an effective amt. of a compd. or compn. or . Prepn. and activity of selected compds. of the invention a luded
AN 1996:13285 CAPLUS
DN 124:165243
TI Anti-inflammatory benzenesulfonic acid d tives, their preparation, and their activity
IN Dixon, Jame ; Hall, Raplh F. Marsh l ga A.; Chilton, Floyd H., III; Mayer, Ralph J.; Winkler, James D.
PA SmithKline Beecham Corp., USA
SO U.S., 16 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	A	TIC N	DATE
PI	US 5470882	A	19951128	U	1-25	19940602
	WO 9533712	A1	19951214	W	5-US6677	19950602
	W: JP, US					
	RW: AT, BE, CH, DE, DK, ES, FR, GB,				E, IT, LU, MC, NL, PT, SE	
	EP 765305	A1	19970402	EP	-922898	19950602
	EP 765305	B1	19991215			
	R: BE, CH, DE, FR, GB, IT, LI, NL					
	JP 10506092	T2	19980616	JP	50 061	19950602
	US 5912270	A	19990615	U	-73 50	19961122
PRAI	US 1994-252716		19940602			
	WO 1995-US6677		19950602			

OS MARPAT 124:161243

IT **447-64-3**
RL: BAC (Biological activity or effector, ept adverse); THU (Therapeutic use); BIOL (Biological study SES (Uses)
(anti-inflammatory benzenesulfonic ac. rivs., their prepn., and their activity)

RN 447-64-3 CAP US

CN Benzenesulfonic acid, 5-(1,1-dimethylpro 2-[(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]car ami]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2002 .
GI



I

AB This invention relates to the novel comp and pharmaceutical compns. of formula I wherein R1 is (CH2)n H or (CH2 R8 ; n is 0 or an integer

having a value of 1; X is oxygen or sulf... R2 is hydrogen, **halogen,** optionally substituted C1-8 alkyl, **or** C1... alkox... m is an **integer having** a value of 1 or 2; R3 is C(O)R7 ; **R4 is** hydrogen, halogen, CF3, CH3, (CH2)tCO2R9 ...gen, or C1-4 **alkyl; R5 is** ...CH2)tCO; t is **0 or an** integer having a value of 1 or 2; R6 is ...gen or halogen; **R7 is NR9R10** ; R8 is hydrogen or C1-4 alkyl; R9 is hy... n or C1-4 alkyl; **R10 is** hydrogen, optionally substituted aryl, o... ally substituted **arylC1-2** alkyl, optionally substituted C1-8 alkyl, ... together R9 **and R10 with the** nitrogen to which they are attached form... to 5-membered **satd. or** unsatd. ring which may optionally compri... additional heteroatom **selected** from O/N or sulfur; or a pharmaceutically ...cept... salt **thereof. This** invention also relates to a method of tre... ...ducing **inflammation in** a mammal in need thereof, which comprises ...ini...ering to **said mammal an** effective amt. of a compd. or compn. of ...hus (e.g., **benzhydrol** 2-[2-[3-(4-bromophenyl)ureido]-4-(triflu... ...hyl phenoxy]**benzoate (prepn.** given) was hydrogenated over 10% Pd/C to ...d 2-[2-[3-(4-bromophenyl)ureido]-4-(trifluoromethyl)p... ...]benzoic acid **which** inhibited PLA2 and CoA-IT at 50 .mu.M or ...

AN 1995:838690 CAPLUS

DN 124:8418

TI ...ntiinflammatory (ureidophenoxy)benzoic ... and ...ivatives **as** inhibitors of phospholipase A2 and CoA-in... ende... ansacylase

IN Adams, Jerry L.; Hall, Ralph F.; Seibel, ...ge...

PA SmithKline Beecham Corp., USA

SO U.S., 17 pp.
CODEN: USXXAA

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPL...	TIO... NO.	DATE
PI	US 5447957	A	19950905	US ...-...		19940602
	WO 9533460	A1	19951214	WO ...-US ...		19950602
	W: ...D, ...S					
	RW: ...L, ...L, CH, DE, DK, ES, FR, GB, G...				...T, ...U, MC, **NL, PT, SE**	
PRAI	US 1994-253...		19940602			
OS	MARPAT 124:...					

IT **171103-10-9P**

RL: BAC (Biological activity or effector, ...ept adverse); **SPN (Synthetic** preparation); THU (Therapeutic use); BIOL... ...logical study); **PREP** (Preparation); USES (Uses)
(antiinflammatory (ureidophenoxy)benzoic ... derivs. **as** inhibitors of phospholipase A2 and CoA ... transacylase)

RN 171103-10-9 CAPLUS

CN ...benzoic ...id, 2-[2-[[[3,5-bis(trifluorom... ...phenyl]amino]**carbonyl]amino** phenoxy]-... (9CI) (CA INDEX NAME)





L5 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2002 AC

AB The enzyme CoA-independent transacylase (C IT) has been proposed to mediate the movement of arachidonate betwe specific phospholipid subclasses, and we have shown that two inh tor of CoA-IT (SK&F 98625 and SK&F 45[illegible]) block this movement. In t we use these inhibitors to further characte the rol in the prodn. of lipid m ators. SK&F 98625 (Et 2-oxo-2,3-dihydro-7-(3,4 [2-[3-(4-chloro-3-imidazol 1-yl)heptane-phosphonate) and SK& trifluoromethylphenyl)ureido] ethy] -4,5-trifluorom dichlorobenzenesulfonic acid inhibited Co ity (IC50 values of 9 .mu.M and 6 .mu.M, resp.). Another compd. any effect on cyclooxygenase, 14-kDa PLA2 acetyltrans ase activities at concns. below 20 .mu.M. However, SK&F 45905 inhib d 85 kDa PLA2 activity (IC50 = 3 .mu.M), and both compds. inhibited 5-l xygenase activity (IC50 values of 4 .mu.M). In ionophore-stimul d neutrophils, SK&F 98625 and SK&F 45905 blocked the liberation of arach from phosphospholipids, which suggest that the movement of arachi specific phospholipid pools is a pre- site for r both compds. also inhibited the prodn. of platele activatir ionophore-stimulated neutrophils and antigen-stimulated mast ce inhibition of platelet-activating factor and arachidonic release was not mimicked by an inhibitor of 5-lipoxygenase, zileuto which indicates that the primary mode of action of SK&F 98625 and SK 45905 via inhibition of CoA-IT. SK&F 98625 and SK&F 45[illegible] were ab reduce prostaglandin prodn. in several inflammatory cells and t of inflammation in ears of phorbol ester-challenged mice. Ta these results show that blockade of CoA-IT, which leads to ir arachidonate remodeling between phospholipids, results attenuation of platelet activating factor prod , arachid d release and the formati of eicosanoid prod cts.

AN 1998:92:639 CAPLUS

DN 128:[illegible]

TI Effects of CoA-independent t[illegible]ase i the production of lipid inflammatory mediators

AU Winkler, Jame D.; Fonteh, [illegible] N.; Sung eravi, Javid D.; Nixon, And B.; Chabot-Fletch , Marie; [illegible]; Marshall, Lisa A.; Chi , Lloyd H.

CS D[illegible], SmithKline eecham Pharm. ssia, PA, USA

SO J. Pharmacol. Exp. Ther. (1 5) 27[illegible](3), 1 CODEN: JPETAB; ISSN: 0022-3[illegible]

DT Journal

LA English

IT 162793-6[illegible]-7, KF 45905
RL: BAC (Biological activity or effector, me ne); BIOL (Biological study,

(effects of CoA-independent transacylase inhibitors on the prodn. of lipid inflammatory mediators)

PI 92793-07-7 APRIS

CN Benzenesulfonic acid, 4,5-dichloro-2-[2-[[2-[(trifluoromethyl)phenyl]amino]acetyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2002 ACS

AB The enzyme CoA-independent transacylase (CoA-IT) has been proposed to mediate the movement of arachidonate between phospholipid subclasses and influence the formation of arachidonic acid esters and platelet-activating factor. To substantiate the role of CoA-IT, the authors have developed two structurally distinct inhibitors of CoA-IT activity, SK&F 98625 [diethyl 7-(2-oxo-2,3-dihydro-4,5-diphenyl-1H-imidazole-1-yl)heptane phosphonate] and SK&F 45905 [2-[2-[2-(4-chloro-3-(trifluoromethyl)phenyl)ureido]-4-(trifluoromethoxy)phenoxy]-4,5-dichlorobenzenesulfonic acid]. These compounds were tested for their capacity to block microsomal CoA-IT activity in two assay systems, the transacylation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (GPC) and the transfer of [14C]arachidonate from 1-acyl-2-arachidonoyl-GPC to lyso-PE. Both SK&F 98625 and SK&F 45905 inhibited CoA-IT activity (IC50s 6-19 .mu.M) in these two assays. In contrast, SK&F 98625 or SK&F 45905 had little or no effect on other lipid-modifying activities, including CoA-dependent acyltransferase or acetyltransferase activities. Kinetic anal. revealed that both SK&F 98625 and SK&F 45905 interact directly with the enzyme and prevented the acylation of lysophospholids in a competitive manner. In intact human neutrophils, both SK&F 98625 and SK&F 45905 completely blocked the movement of [3H]arachidonate from 1-acyl-linked phospholipids into 1-alkyl-2-arachidonoyl and alk-1'-enyl-2-arachidonoyl-GPE. In contrast, these compounds did not inhibit the incorporation of free arachidonic acid into phospholipids indicating that they did not alter CoA-dependent acyltransferase activities in the intact cell. This is the first report to describe an inhibitor to address the importance of CoA-IT in arachidonate-phospholipid remodeling. These results provide further evidence that CoA-IT mediates the movement of arachidonate into the large pool of ether-linked phospholipids in human neutrophils and suggest that it may be possible to regulate AA levels in cellular phospholipids with CoA-IT inhibitors.

AN 1995:495164 APLUS

DN 132:259557
TI Inhibitors of Co[illegible] independent [illegible]s[illegible] [illegible]las[illegible]ol movement of arachidonate [illegible]nto 1-ether [illegible]phosphol[illegible] [illegible]man neutrophils
AU Cl[illegible]lton, [illegible] H[illegible] Fonteh, [illegible] N.; Sun[illegible]; Hickey, Deirdre M.; [illegible] Torph[illegible], I[illegible]e J.; Hay[illegible]uth[illegible].; [illegible]a[illegible]isa A.; Heravi, Javid [illegible]; Winkler, Mar[illegible] D.
CS [illegible]ction on Pulmo[illegible]y and Cr[illegible] Ca[illegible] Me[illegible]e [illegible]man Gray School of [illegible]dicine, Winsto[illegible]alem, NC [illegible]7-[illegible]4, [illegible]
SO [illegible]iochemistry (19[illegible], 34(16), [illegible]-1[illegible]
[illegible]DEN: BICHAW; ISSN: 0006-29[illegible]
DT Journal
LA English
IT 162793-63-7
PL: BAC (Biological activity or effector, [illegible]pt[illegible]erse); BIOL (Biological study)
(inhibitors of CoA-independent transacylase for movement of arachidonate into 1-ether-linked phospholipids of human neutrophils)
RN 162793-63-7 CAPLUS
CN [illegible]benzenesulfonic acid, 4,5-dichloro-2-[[[3-chloro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L[illegible] ANSWER 22 OF [illegible]2 CAPLUS COPYRIGHT [illegible]2002 ACS



AB The title material contains a p no cyan ple which is 2-substituted with a ureido group Q1 and 5-st ti ited R1C O2R2CONH [Q2 = NR4, O; R1 = (cyclo)alkyl, aryl, heterc cle ; R2 yl ; R3 = H, substituent; n = 1-4; R4 = H, alkyl, aryl, h r cyc = substituent except CN]. Thus, a soln. of the title cyan ler i- phth ate and EtOAc contg. alkyl naphthalenesulfona a d ge va ixed with a red-sensitive AgBr emulsion th oated c pr este support to give a photog. film, wh h gave fog- pr nted e h coloring property.

AN 1991:618758 CAPLUS

DN 115:218758

TI Silver halide color photograph emulsion eric containing ureido-substituted phenol cyan upler

IN Nakayama, Noritaka; Masukawa, T ai

PA Konica Co., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03080241	A2	19910405	JP -21 0	19890824

IT 136925-86-5
RL: USES (Uses)
(cyan coupler, for silver h phot uls n, prevention of fog in)

RN 136925-86-5 CAPLUS

CN Butanamide, 2-[(decylamino)sulf [2-ox -(4 ethoxyphenoxy)-4-[[[3-(trifluoromethyl)phenyl]... carbo mi phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2002 A
G



I

AB The title compds. [I; R1 = H, halo, CF3; R4, R5 = H, halo; R3 = halo, CF3, CF3O, CF3SO2; R6 = NR7R8, CO2R11, COR9, SO2R9; R7 = R8 = H, alkoxycarbonylethyl, COR9, SO2R9; R9 = substituted alkyl, alkenyl, alkynyl, Ph(CH2), naphthyl, pyridyl, furyl, thienyl, (un)substituted alkyl, Ph, naphthyl, pyridyl, pyrimidyl, thienyl; R11 = H, halo; R12 = alkyl] were prepd. as herbicides and plant growth regulators (no data), e.g., by etherification of aminohydroxybenzonitriles with halobenzenes. Thus, 3,4,5-trichlorobenzotrifluoride was added dropwise to a pre-stirred mixt. of 2-amino-4-hydroxybenzonitrile and NaOH in DMSO and the whole was stirred for 5 h at 90.degree. and 2 h at 90.degree. to give 85% title compd. I (R1 = R5 = Cl, R3 = R4 = H, R2 = CF3, R6 = NH2).

AN 1991:101367 CAPLUS

DN 114:101367

TI Preparation of phenoxybenzonitriles as herbicides and plant growth regulators

IN Busse, Ulrich; Santel, Hans Joachim; Schmidt, Robert R.; Luerssen, Klaus; Strang, Hans

PA Bayer A.-G., Fed. Rep. Ger.

SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 379015	A1	19900801	EP 1990-100113	19900104

R: BE, CH, DE, FR, GB, IT, NL

JP 02233650 A2 19900917 JP 11 19900123

PRAI DE 1989-3 8 19890126

OS MARPAT 1 0 367

IT **132147-05-8P**

RL: AGR (Agricultural use); BIOL (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as herbicide and plant growth regulator)

RN 132147-05-8 CAPLUS

CN Urea, N-[2-cyano-5-[2,6-dichloro-4-(trifluoromethyl)phenoxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) INDEX NAME)



L1 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2002

G



A1 N=N-Z3 Z2-N=N-

AB In the title photoreceptor having an conductive support a photoconductive layer, the photoconductive layer contains a **trisazo** pigment I (Z1, Z2, Z3 = arylene, heterocyclic; = methylene; **A1, A2,** A3 = coupler residue having phenolic OH)

AN 1989:163564 CAPLUS

DN 110:163564

TI Electrophotographic photoreceptor containing charge-generating **trisazo** pigments

IN Miyazaki, Hajime; Takai, Hideyuki; Yoshihiro

PA Canon K.K., Japan

SO Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63282	A2	1 8811	JP 11	8 370515
JP 256 0		1 0512		

IT **119956-25-5**

RL: USES (Uses)

(electr p tog. charg n pig for mpro d sensitivity)

RN 119956-95-5 APLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1 5-dihydro-2-[4-[[2-hydroxy-3-[[[[[3-(trifluoromethyl)phenyl]carbamoyl]-11H-benzo[a]carbazol-1-yl]azo]phenyl]3,3-methylenebis[6-methyl-4,1-phenyleneazo]]bis[3-hydroxy-N-[3-methoxyphenyl]amino]carbonyl]- (C CA INDEX NAME)

PAGE 1-A



PAGE 1-B



CF3

OPh

L ANSWER 2 OF 2 PLUS ONLINE 02
G

P nt selecte from Ch e se sic 102



I

A The title compds. [I; R1 R2 = h o, alk . (halo)alkoxy, (halo)alkylthio, (un)substituted ary oxy = n substituted alkylene, optionally with 1 or 2 O inte ter or t he Ph group with 1 or 2 O; R3, R4 = H, halo, halo)a l, hal y; (un substituted cycloalkyl; X = O, S] we e pre as pes nst animal pests, esp. insects and ararids. 4- 2-Ch 2 3,3-t or clobutyl)nitrobenzene was hydrogenated er Raney Ni e re g iline was condensed with 3-isocyanato-1-phe lfura giv 1-F = H, R5 = 4-(2-chloro-3,3-trifluoroc), (. Tested against Tetranychus tic egg and n b an II gave 100% kill of all stages, compared to -62 er fu anyl insecticides.

AN 1988:150483 CAPLUS

DN 108:150483

T Preparation of 1-phenyl-3-(4 zl-3-fu)u as s pesticides

IN Sirrenberg, Wilhelm; Mar old, ec t; s. bert

PA Bayer A.-G., Fed. Rep. r.

SO Ger. Offen., 29 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
P	DE 3621 62	A1	880	DE 62 62	19860708
	US 4853397	A	890	US 6	19870625
	EP 253175	A2	880	EP 3	19870626
	EP 253175	A3	1 3902		
	EP 253175	B1	9210		
	R: AT, BE, CH DE, R, GR , I,				
	AT 4031		930	AT 10 9	19870626
	JP 6301 871	A2	880	JP 6	19870706
	DK 8703503	A	880	DK 350	19870707
	HU 4417		880	HU 306	19870707
	ZA 870 18	A	888	ZA 9	19870707
P	DE 1986-3621862		860		
	EP 1987-109220		870		

CA CASREACT 108:150483; MARPAT 108:150483

IT 113664-71-4P
RL: AGR (Agricultural use); BIOL (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of as nsecticide)

RN 113664-71-4 CAPLUS

CN Urea, N-[4-(2-chloro-2,3,3-trifluorocyclobutyl)-3-trifluoromethyl)phenyl]-N'-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)

P nt selected from Ch e se sic e 3

nt select



ANSWER ... PLUS
Coccidi... by ... of a polyether
antibio... carbanilide in
feeding ... A ... monensin
[17090-...] ... (trifluoromethyl)-4,4'-
dichloro carbanilide ... no. of combinations
were evaluated ... cervulina and
E. tene... ...icacy to the
compds. ... f
3-nitro... with
2,4-din...
2-amino ... ,4
...3-
... 95:1
Anti... and
carbani...
Lilly, ...
C..., 54 pp
CODEN: ...XX
Patent
English
CA ... 1222
US ... 0506
US ... 0518
US 1979 ...
US 1981 ...50...
ses)

nt select ... s

C ea, N-), flu]] (4 noxy)phenyl]-
(9CI) (E)



C

L ANSWER 27 OF 3 LUS 2 02
A Anilin s RZC6H+ R = g lor p zinyl, Z = O,
SO2) we e p erd c e esp ureas, carbamates,
carboxamides, a nze de men cyanates,
chloro acy
A 1984:5 CA
D 101:1
T Synthes of po al an des from
substituted ani
A Kempter, Gerhar erb
C Sekt. Chem./B aed sch "P ebk ",
Potsdam Sanssc DR- De
S Wiss. Paedag foch k Pot , 27(1),
101-20
CODEN: PHLA 01
D Journal
L German
C CA 101:11
I 91619-5 -5P
RL: SPN Synthet rep (P tion
(prepn. of)
P 91619-5 CA
C Urea, -[4-(3- nyl), -1 [luo phenyl]- (9CI)
(CA X NAME



L ANSWER 28 OF 2 LUS 2
C



AB Triazinetriones [R = substituted a alkenyl, cycloalkyl, Ph; R1 = H, alkyl, acyl, alkali, halo, cyano, NO2; R3 = substituted Ph] were prepared by reaction of 3-[3-chloro-4-(trifluoromethyl)phenoxy]phenylurea with R4CONCO (R4 = halo, alkyl, acyl). For example, 3-[3-chloro-4-(trifluoromethyl)phenoxy]phenylurea was treated with ClCONCO to give 8% I [R = H, R2 = 2,4 Cl(F3C)C6H3]. I are effective herbicides at 3.0 kg

AN 1983:408238 CAPLUS

DN 99:88238

TI 1,3,5-Triazinones and their use for controlling undesired plant growth

IN Parg, Adolf; Hammann, Ingeborg; Wenner

PA BASF A.-G., Fed. Rep.

SO Ger. Offen., 55

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3147879		5	DE 3147 79	1981 1203
	EP 811		5	EP 1108 9	1982 1124
	EP 811		1		
	EP 811 2		25		
	R: AT, BE, DE,		B, , L ,		
	JP 58103374		0	204	19 1124
	CA 1175374		2	416	1984 1124
	AT 20528			1108 9	1982 1124
	IR 8206946			694	1982 1130
	ZA 8206 57			885	1982 1202
	HU 30900		8	388	1982 1202
	HU 1883		3		
	US 4511 97		3	4620	1985 0128

PRAI DE 1981-3147879 3
DE 1982-3201229 5
EP 19 -10859 4
US 1982-446064

OS CASREACT 99:88238

GI 86819-5 -2

RE. FORMAT Reactant
(cyclocondensation of aryl is c s)

RE 865 2 CAPLUS

CA Prep. of 3-[2 -4 rc eth]phenyl-N'-[3-trifluoromethoxy A E)



P

L ANSWER OF 3 IGI 2
C.



P

AB The title compd. I; R O2, c tion ly ogen-substituted alkyl, a oxy, al v.thic finyl, ulfonyl; R2 = alkyl, haloaky , alkox , alo, o, CO H H, alo, c ano, NO2; R4 = halo, (un)subst. ed nyl, yl, h; R5 = H, alkyl, haloacy , alka tal, were p. by clocondensing phenoxyphenyl s wi i ocya te hus. N-[-[2-chloro-4-trifluorometh nox hy rea was treated with ClCONCO to gi T , l = = R - H = NO2, R4 = Me). I are be ber agains hem di n album, than 1-[4-[2-chloro if hy)phe yl- met ,3,5-triazine-2,4,6(1H,3H,5H one.

AN 1983:47 73 CA
DN 99:7077
TI 1,3,5-T.iazino nd n com nder red t growth
IN Parg, Wolf; Hamp cht Wuerzb
PA BASF A. G. , Fe ep.
SO Ger. Pat. Appl. pp.
CODEN: DBXXDW
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE
EP 8114	A	110 9 1124
EP 8114	B2	
EP 8114	B	
R: AT, BE DE, , T, L ,		
DE 3147 9		141 79 19 11203
DE 3201 29		320 79 19 20116
AU 20526		110 9 9821124

PRAI DE 1981-3147879
DE 1982 012
EP 1982- 085
CASREACT 99:70
RN 86607-45-6

I nt selec[illegible] fro[illegible] / 7/20 [illegible]

L: RCT [illegible] (cy[illegible] cold[illegible] [illegible]cyl is[illegible] s)
P 6607[illegible] 6 C[illegible]
C rea, [illegible]5-[2 [illegible]-4 [illegible]omethy[illegible] yl[illegible] nitr[illegible]enyl]-N'-[3-trifluo[illegible]romethy[illegible]ny[illegible] (CA I[illegible] I E[illegible]



I ANSWER [illegible] OF 2[illegible] [illegible]PLU[illegible] [illegible]IT 20 2[illegible] 3
C



A Anticoccidial c[illegible]ns. [illegible] eedstu[illegible] [illegible]mix s fo[illegible] poultry such as chicken or turk[illegible] contr[illegible] [illegible]binati[illegible] [illegible]olye[illegible]her antibiotic and a carbanilide I [illegible], R2, ar[illegible] [illegible], halog[illegible], NH[illegible] NO2, C1-6 alkyl, C2-4 alkanoy[illegible]amino, [illegible] alkyl [illegible]ubstit[illegible]t [illegible]noxy[illegible] et[illegible]; R4 and R5 = H or C1-4 al[illegible] [illegible] P[illegible] and [illegible] [illegible]alloge[illegible] H2, [illegible]-4 [illegible]aloalkenyloxy, etc.). [illegible], [illegible] mix [illegible] [illegible]amino [illegible]o-3[illegible] d[illegible]tro-5-trifluo[illegible]rometh[illegible] [illegible]ba[illegible] [illegible]6393-2[illegible] mo[illegible]nsir [17090-79-8] each at 50 p[illegible] effe[illegible] [illegible]y [illegible] [illegible] cocci[illegible] [illegible] n 1[illegible] br[illegible]er chicks infecte[illegible] with [illegible] [illegible]a [illegible] and E[illegible] [illegible]ne a.
A 981:71[illegible] 8 C[illegible]
I 94:7142[illegible]
T Anticoc[illegible]dial [illegible]osit[illegible] a bani[illegible]d
I[illegible] Callendo[illegible], Mar[illegible] Eme[illegible]so[illegible] [illegible]rs, [illegible]hc [illegible]rk; [illegible]Do[illegible]y, George Oliver Plunkett; Clinto[illegible], Albert Billy, [illegible] and [illegible], USA
S Pur. Pat[illegible] pp[illegible]
CODEN: [illegible] X[illegible]D[illegible]
D Patent
L English
F[illegible] CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
P[illegible]	EP 1511[illegible]	A2	EP [illegible]	00211
	EP 151[illegible]	A3		
	EP 151[illegible]	B1		
	R: [illegible]E [illegible]	FR, G[illegible]	[illegible]U, NL,	
	US 421[illegible] 8	19	US 121	790214
	GB 1[illegible]99	[illegible]	GB 447	800211
	AU 805[illegible]	A1	19 AU 5546	800212
	AU 531[illegible]	B2	1	
	ZA 800[illegible]	A	1 ZA 9[illegible]91	800212

F[illegible] nt [illegible]elec[illegible]d [illegible]com [illegible]ne [illegible]e. [illegible] 1Page 5

JL 59379	A1	19	IT 593		800212
E 8814		19	B 97		00213
K 8006 2		19	DE 9 12		00213
P 5512033		19	JP 3 [illegible]		00213
P 01047447	A	19			
R 2456		19	FR 7		800213
FR 2456 3	A1	19			
S 4885	A1	19	ES 488 3		9800213
AT 8000 2		19	AT 762		9800213
AT 369	B	198			
CA 1136 46	A1	19	CA 345		800213
U 2831		19	H 327		800213
HU 185		19			
CH 6127		19	CH 7		800213
EP 8600 50		19	EP 50		00214
EP 7148		19			
EP 71		19			
US 42	A1	19	US 58		820917
ES 197 65		19			

I 2063-6
L: BIO (Biolo l stud
(antico) ompn. polyeth a
P 2063-69-6 CA
C rea, N-[3 ifluo phen l - lo enoxy)**phenyl]-**
Cl) (A IN E)



C 3

I ANSWER CF 3 LU HT 20 2
G For dia a(s), pr ssue.
A ighty ig t (t res O or ; 2 3-CF3, **or 4-Me;**
l = e Me , eS, -CCl HC Cl 4C r
-[4-(3 CF 5C NH C R2 = e. 4 C 5 5-**CF3, or**
-ClCH: g. H or 4 C CF3, **or 5-Cl],**
sed in t of osis n e fd. **in 75-90%**
ield by react pie hio)a e ani in **inert**
olvents conta rtia base ter
A 1975:13 8
D 82:139
T Diphe y lo
I ether, fg chem Huber ; ; Winkelmann,
Eduard
P Farbwer oech -C.
S ger. Of
CODEN: X
I alent
I rman
P C T
PATENT D Y E OF E

I DE 2334355 A1 1· DE ·· ·· 65 30706

I **2063-69-6P**
RL: PREP (Prepa ·tion)
(manuf. ·· dio·
P 2063-69-6 CAP
C Urea, N 3, ·· ·lfl· pher ·] · ·lo· henoxy)**phenyl]-**
(9CI) CA IN· ·E)



C

I ANSWER ·· ·LU· ·T 20·
A I, II, III, a · are p· ·d tes· · · ·· ·· ·· as **Helix,**
Arion, Limax, ·erar, ·s, B·· ·· ·· Australorbis
glabrat·s, an· ·· ·e·s ··3 g p · ·· ·2 · ·0 **ml. dioxane**
32.2 g. ·,·-C ·6H·· ml. dio a ·ed · ·wise **and after**
30 min. ·· ml. · r · ·ive 4 · · R = · = **R2 = R5 = H,**
R3 = CF·, ·· - m. · ·egre · · · ·· ated **compds. are**
effective · j· ·· g · · c· pr · · ·· tive **compd., 0.5**
ml. "Tw·en ·· " 5 ·· ·· in Me2 · · ·· ·sed.
Alternative ·y · ·· so p·ep m · · CSNMeOMe, **and**
1-napht·l · ·· ·ur· ·.de· ·· · · **are given for**
water-x·e· ns. ·easu · ·· en **appear. The**
compds. ·r· d ·) ·· ·n th· ·
A 1969:49 ··· ·
D 71:910·
T Urea and · o· ·riv· ·seful ga ·l ·cs a snails
P CIBA Ltd.
S Fr., 9 pp.
CODEN: ·RX· ·X
D Patent
L French
F .CNT 1
PATENT NO. ·D ·· · ·· ·E
-------- · -- · ---
P FR ·5·· ·· 1
P·I C· 1
I 22751-58-4·
RL: SP· ·· ·t · ·re· · PRE· · · ·n
(prepn. of
R 237·1-·· ·· ·
C Carbanil·d· ·· ·ro- · ·,5 ·b ·no · · - **(8CI) (CA**
·NDEX ·· ·

F nt select d



= d is

FILE 'HOME' F 13 ON 1

FILE 'RLG STR' (FEB 5 15:55:43 ON 1
I STRUCTURE UPLOADED
I 13 S L
I 365 S L

FILE 'USPA FU' AT AT 15:5 1 CH 2
I 17 S 3

FILE 'CAPLUS' ON 3
I 32 S L

= s l5 and cancer
163322 CAN
22750 AN
170006 CAN
OR CAN
I 6 L5 CP

= d bs bib fhits

I ANSWER 1 OF 6 S E 2002 AC
A Chem. structures e fies wh modify pyruvate
kinase and in i Th used as
pharmaceutica the fo es and
disorders ie fluencin l, e.g. the
glycolytic pa which source, and
all pathways vo phos e lat to the delivery
of oxygen g b n affin ents tumor and
cancer and Al Prep.
-phenylethyla o acid e
A 2001:860018
I 134:700
T Allosteric in s kinase use
A Abraham, D ia ng; ar ; Burnett,
James C.; os
P USA
S U.S. Pat. 5 nt. .379.
CODEN:
I cent
L g ish
F .CNT 2
TENT NO. AP PE

P 2001 U 307

F nt select s s

'S 6214 '9 .00 80324
P I 'S 1998 16 3 99
I .89060-07-7
'L: BSU (B ical activity);
HU (Thera ogi
(pyruvate ki se)
P 89060-C7-
C ,3-Benzenedic 3-
(trifluo ethyl ester
9CI)



I ANSWER OF 6
C

* TR CTURE DIAGRAM AY NE PRINT *

A Title compd . phthyl; L = H,
,6-(CH3)2, 2 (CH3)3CNHCO,
CH3(CH2)5NHCO, HCO,
-CH3C6H NHCO. NHCO; q = 0-8;
m = 0-8; n = (acce useful as
therapeutic a or pre ents pemia,
arterioscleros cancers, epd. II
was prepd.
A 2000:742094
I 33:296435
Preparation o use s. hyperlipemia,
arterioscle
I Fujita, Takesh o; Fujiwara,
Toshihir
P Sankyo Company
S PCT Int. Appl.
CODEN: PIXXD2
D Patent
L Japanese
F CNT 1
PATENT NO. ND A
------ -- - - ---
P 'O 2000 .0 0406

P nt select f om

W: U, BP C D, PL, RU, TR,
US,
RW: T, BE C LU, MC, NL,
T,
P 2000 406
P 116 406
R: , E S , BE, MC, PT,

BR 2000 406
NO 2001 011005
P JP 1999
WO 2000
C MARPAT 133:
I 301548-
PL: BAC BSU (Biological
study, ; n ic apeutic use);
BIOL (B ; a
(pre s yperlipemia,
arte d e
P 301548-
C Urea, N [3- [2 b-thia noxy]methyl]-1-
methyl- benz c thyl)phenyl]-
(CI) A F

A



B



P CNT 16 LCORD
A E N

I A SWER GHT
C

P nt select f m 17: Pag

I nt selecte f ...6/0 /2...

M 

A This in...t or ...prepn. ... ...ureas ANHCONHR ...; A ... 5- or 6... ... esp. Ph or pyridin... ; M ...ging ... ; L1 = ...st one (un)sub...ituted ...fa... ...rbox..., ... ; q = 1-3; B = certain ...un,sub...tuted ... to tri... ... ... groups] for the trea...me... ...f... ... disease ... cer data). ...Appr... ... in... ...nds. ... ...diates were prepd. ...r ... ...e, ... tuty...n ... bis(tric...loro... ... ...to form ... ...owed by addn. of 4-(3-N-m...thy... ... ...ni...ing ... ...rd the urea II.

A ...090:49 ...

I ...133:120

T Prepara...on of ...(hete... ...nyl ureas as raf kina... ...inh... ...

I Riedl, B...nd; ..., C... Kh...e, ... B.; Scott, William ...; ...m ...Roge... ...d ... ...therine; Matero, ...

P Bayer Co...ora... ...

S PCT Int. ...ppl ...

CODEN: ...IDD

D ...tent

L ...nglis...

F ...CNT 1

PATENT N...	...	...	...	...	...
P ...O 2000...10 ...	...	...	...	...	...112
W: ...AU, ...	...	...	...	...	..., CN, CR, CU,
..., CZ, ...	...	...	...	...	..., HU, ID, IL,
..., ...	...	...	...	...	..., LU, LV, MA,
...MD, MG...	...	...	...	...	..., SE, SG, SI,
..., TR, ...	...	...	...	...	...U, ZA, ZW, AM,
..., ...	...	...	...	...	...
RW: ...H, ...	...	...	...	...	...CH, CY, DE,
..., ...	...	...	...	...	...BF, BJ, CF,
...S, C...	...	...	...	...	...
EP 1140...	...	...	...	...	...112
R: ...T, BE...	...	...	...	...	...SE, MC, PT,
...E, S...	...	...	...	...	...
US 20010... 135	...	...	...	...	10202
US 2001... 113	...	...	...	...	...202
US 200... 65...	...	...	...	...	...202
US 2001... 2...	...	...	...	...	...202
US 2001... 4...	...	...	...	...	...202
WO 200... 246...	...	...	...	...	...12
US 200... ...	...	...	...	...	...210
P US 1999... 5...7...	...	...	...	...	...
US 1999... 7266	...	...	...	...	...
US 1999... 5...2...	...	...	...	...	...

I nt selecte f... ... ...7:...Pa...

F nt selected i [illegible] /0 2

WO 2000 [illegible]
C MARPAT [illegible]
3 284461-4 [illegible]
RL: BAC [illegible] (Biological study, u [illegible]); THU (Therapeut [illegible]); RACT (Reactant [illegible]); [illegible] (prepn. [illegible] urea raf kinase i [illegible] ng [illegible] lamines)
F 284461-1 -3
C 2-Pyrid [illegible] phenyl]amino] carbony [illegible]



M [illegible]

F N 12 [illegible] ORD

1 ANSWER 4 O 6 [illegible] LUS [illegible] HT 200 [illegible]
A A method of tr [illegible] ing a [illegible] lated [illegible] nger comprises a [illegible] trat [illegible] "CO" [illegible] H, pyridyl, 2-thienyl; B [illegible] ui st [illegible] yl [illegible] reg.1 6-membered [illegible]rom. struc [illegible]), [illegible] tyl-2-(3-tetrahydrot [illegible] oc anate were tirred [illegible] tetrahy [illegible] le compds. inhibi [illegible]
A 1999:42 [illegible]
D 131:58 [illegible]
T Preparation o [illegible] inhibi [illegible]
I Miller, Sc [illegible] n; Dur [illegible] dow; Lowinger, Timothy Brun [illegible] ott [illegible] ger A.; Wood, Jill E.; Gun [illegible] Vokdad, [illegible] ell; Sibley, Robert; [illegible]
P Bayer Co [illegible]
S CT Int. A [illegible]
CODEN: [illegible]
D Patent
L English
F CIT 1
PATENT [illegible]

F WO 993248 [illegible] 222
W: AL, A [illegible], CZ, DE, [illegible], IN, IS, JP, [illegible], MG, MK, MN, [illegible], TJ, TM, [illegible], RU, TJ, TM
RW: [illegible] SZ, [illegible], DE, DK, ES, [illegible] LU, M [illegible], CF, CG, CI,

F nt selecte from [illegible]

F it selecte. fro

CA 2315
AU 99193
EP 1042305
R: AT, PL, D FP, E, SE, MC, PT,
JP 20015 6276 8 2
F US 199 774
O 1998 3072
C ARPAT 131:5
28399-63-2P
B: BAC ; B (Biological
study, ; GI eutic use);
BIOL (B
(prep
F 28399-6
C rea, N- me
ethylph oxy



F 5 RECORD

I ANSWER 5 (AC
C



F N

I The title d [Pl a epr nt kyl, or R1 and
2 toge ori to C me; rep ; W represents
CH or N; d) esc ub ar heteroaryl] are
prepd. nh b de wt

selecte fro 6

autophos[illegible] a[illegible] d[illegible] the of ncer,
Arthrit[illegible] pre (a 0 mg/kg i.p.
once daily f[illegible] ur[illegible] e transplanted
Leukemic P[illegible]

1997:414195 A.

27:34137

Preparation[illegible] ol[illegible] ac biting
platelet-de[illegible] e owth on
Tubo, Kazuo[illegible] is oba, Tsuyoshi;
Kato, Shinich[illegible] o; al.
Kirin Be[illegible] K[illegible] am Shinichi;
Shimizu Toshiy[illegible] ch

PCT Int. Appl., [illegible]
CODEN: PIXXD2
Patent
Japanese
CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9717309			WO	961105
W: [illegible], AM, AU, BB, BG, BB				CH, CN, CU, CZ, DE,
[illegible]				KG, KZ, LC, LK,
[illegible]				MG, PL, PT, RO,
RU, [illegible]				SG, UZ, VN, AM,
AZ, [illegible]				
RW: KE, [illegible]				AT, FR, GB, GR,
IE, [illegible]				LU, MC, GA, GN, ML,
MR, [illegible]				
AU 9673400	[illegible]		AU 96	961105
EP 860033	[illegible]		EP 9	961105
R: CH, [illegible]				
US 6143[illegible]	[illegible]		US [illegible]	980506

PRAI JP 1995 [illegible]13
JP 1996-[illegible]217
WO 1996 JP[illegible]

CASREACT 127:34[illegible]3
MARPAT 127:34[illegible]3
GI 990727-78-7P
PL: BAC Bi[illegible]g [illegible] ; BSU (Biological
study, un[illegible] [illegible] a[illegible] herapeutic use);
PROL (B[illegible] a[illegible] [illegible] i ; se
(pr[illegible] [illegible] e c i bi g
plat[illegible] [illegible] otc a ho ation)
RE 990727-[illegible]
CA Urea, N-[2,5-[illegible] [illegible]-1] c hoxy-4-
quinolinyl)-[illegible] EX

I .t selecte

M

I



I ANSWER 6 OF
A ET-18-O-CH3 ( ) is an
antipro fer gent, k h ells
both in vit o e regarding the
mechanism l i. pro ti e C independent
transacylas (C T n ate between
specific phosph or y of mammalian
cells. ET- t , 0.5 .mu.M),
and kinetic ana ea hi tive with the
yso-phosph p ly was to explore
he connect ee t o A erative effects
using se al st ti ET-18-O-CH3 and
other i ibitor re o liferation and
ymidine i r. t s l r e apoptosis in
uman HL-60 or a . T m o poptosis induced
by ET-18-O- 3 ar d by tumor
ecrosis fa or a act ar 3, whereas tumor
ecrosis fa o poptosis in this
odel reveal d a st to CoA-IT
nhibitors, i t ry iled to induce
poptosis. ib ; that
articipate ce lipoxygenase and
phospho A er, these results
emonst e that f a ckade of
prolife ation o o 's.
A 996:70 144 (AH
L 26:166148
T Inhibitors o A- ra poptosis in
uman HL-60 e
A kler, Jan Ch a tcher, Marie;
Mayer, Ruth
C Dep. Immunol, naceuticals, King
of Prus
S Journa 96 , 279(2),

P nt selected fr es 6

nt selected fi

56-966
ODEN: JPET
Williams &
Journal
English
162793-63-
RL: BAC (Bio
study, uncla
(inhibito
HL-60 ce
162793-63-7
enzenesulf
trifluorom
(DCI) (C

BSU (Biological
s
ptosis in human
methyl)phenoxy]-



F

nt selected fi



N-(2-methoxy-5-(trifluoromethyl phenyl)-N-(4-(2-carba -pyridyloxy)phenyl)urea



N-(2-methoxy-5-(trifluoromethyl)phenyl)-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

Print selected from Online session15/07/2002

L4 ANSWER 11 OF 17 USPATFULL

AB This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:105872 USPATFULL

TI Anti-inflammatory compounds

IN Dixon, James S., Malvern, PA, United States
Hall, Raplh F., Villanova, PA, United States
Marshall, Lisa A., Wyndmoor, PA, United States
Chilton, III, Floyd H., Pilot Mountain, NC, United States
Mayer, Ruth J., Wayne, PA, United States
Winkler, James D., Fort Washington, PA, United States

PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)

PI US 5470882 19951128

AI US 1994-252716 19940602 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Conrad, III, Joseph M.

LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1612

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **447-64-3**
(anti-inflammatory benzenesulfonic acid derivs., their prepn., and their activity)

RN 447-64-3 USPATFULL

CN Benzenesulfonic acid, 5-(1,1-dimethylpropyl)-2-[4-(trifluoromethyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 17 USPATFULL

AB This invention relates to the novel compounds and pharmaceutical compositions of Formula (I).

This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:80325 USPATFULL

TI Anti-inflammatory compounds

IN Adams, Jerry L., Wayne, PA, United States
Hall, Ralph F., Villanova, PA, United States
Seibel, George L., Wayne, PA, United States
PA SmithKline Beecham Corp., Philadelphia, PA, United States (U.S. corporation)

PI US 5447957 19950905
AI US 1994-252851 19940602 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Barts, Samuel
LREP Dinner, Dara L., Venetianer, Stephen, Lentz, Edward T.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1726

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **171103-10-9P**
(antiinflammatory (ureidophenoxy)benzoic acids and derivs. as inhibitors of phospholipase A2 and CoA-independent transacylase)

RN 171103-10-9 USPATFULL

CN Benzoic acid, 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2002 ACS
GI



II

AB This invention relates to the prepn. and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6-membered (hetero)aryl, esp. Ph or pyridinyl; M = bridging group; L1 = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepd. For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addn. of 4-(3-N-methylcarbamoylphenoxy)aniline (prepn. given) to afford the urea II.

AN 2000:493516 CAPLUS
DN 133:120157
TI Preparation of .omega.-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042012	A1	20000720	WO 2000-US648	20000112
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140840	A1	20011010	EP 2000-903239	20000112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2001011135	A1	20010802	US 2001-773659	20010202
	US 2001011136	A1	20010802	US 2001-773675	20010202
	US 2001016659	A1	20010823	US 2001-773672	20010202

	US 2001027202	A1	20011004	US 2001-773658	20010202
	US 2001034447	A1	20011025	US 2001-773604	20010202
	NO 2001003463	A	20010912	NO 2001-3463	20010712
	US 2002042517	A1	20020411	US 2001-948915	20010910
PRAI	US 1999-115877P	P	19990113		
	US 1999-257266	A2	19990225		
	US 1999-425228	A2	19991022		
	WO 2000-US648	W	20000112		

OS MARPAT 133:120157

IT **284461-42-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-42-3 CAPLUS

CN 2-Pyridinecarboxamide, 4-[3-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Print selected from Online session15/07/2002

L5 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2002 ACS
GI



II

AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepd. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 .mu.M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

AN 2000:493376 CAPLUS
DN 133:120155
TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041698	A1	20000720	WO 2000-US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1158985	A1	20011205	EP 2000-905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	A2	19990225		
	US 1999-425229	A2	19991022		
	WO 2000-US768	W	20000113		

OS MARPAT 133:120155
IT **284461-86-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 284461-86-5 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2002 ACS

AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.

AN 1999:421667 CAPLUS

DN 131:58659

TI Preparation of diaryl ureas as inhibitors of p38 kinase.

IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming

PA Bayer Corporation, USA

SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932463	A1	19990701	WO 1998-US27265	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315715	AA	19990701	CA 1998-2315715	19981222
	AU 9919399	A1	19990712	AU 1999-19399	19981222
	EP 1042305	A1	20001011	EP 1998-964221	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526276	T2	20011218	JP 2000-525400	19981222
PRAI	US 1997-995749	A	19971222		
	WO 1998-US27265	W	19981222		

OS MARPAT 131:58659

IT **228399-63-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)

RN 228399-63-1 CAPLUS

CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Print selected from Online session15/07/2002

L5 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB This invention relates to the novel compds. and pharmaceutical compns. of formula I wherein R1 is (CH2)nOH or (CH2)nCO2R8 ; n is 0 or an integer having a value of 1; X is oxygen or sulfur; R2 is hydrogen, halogen, optionally substituted C1-8 alkyl, or C1-8 alkoxy; m is an integer having a value of 1 or 2; R3 is C(O)R7 ; R4 is hydrogen, or C1-4 alkyl; R5 is hydrogen, halogen, CF3, CH3, (CH2)tCO2R9, or (CH2)tOH; t is 0 or an integer having a value of 1 or 2; R6 is hydrogen or halogen; R7 is NR9R10 ; R8 is hydrogen or C1-4 alkyl; R9 is hydrogen or C1-4 alkyl; R10 is hydrogen, optionally substituted aryl, optionally substituted arylC1-2 alkyl, optionally substituted C1-8 alkyl, or together R9 and R10 with the nitrogen to which they are attached form a 5 to 7 membered satd. or unsatd. ring which may optionally comprise an addnl. heteroatom selected from O/N or sulfur; or a pharmaceutically acceptable salt thereof. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amt. of a compd. or compn. of I. Thus, e.g., benzhydrol 2-[2-[3-(4-bromophenyl)ureido]-4-(trifluoromethyl)phenoxy]benzoate (prepn. given) was hydrogenated over 10% Pd/C to afford 2-[2-[3-(4-bromophenyl)ureido]-4-(trifluoromethyl)phenoxy]benzoic acid which inhibited PLA2 and CoA-IT at 50 .mu.M or less.

AN 1995:838690 CAPLUS
DN 124:8418
TI Antiinflammatory (ureidophenoxy)benzoic acids and derivatives as inhibitors of phospholipase A2 and CoA-independent transacylase
IN Adams, Jerry L.; Hall, Ralph F.; Seibel, George L.
PA SmithKline Beecham Corp., USA
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5447957	A	19950905	US 1994-252851	19940602
	WO 9533460	A1	19951214	WO 1995-US6680	19950602
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-252851		19940602		

OS MARPAT 124:8418
IT **171103-10-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiinflammatory (ureidophenoxy)benzoic acids and derivs. as inhibitors of phospholipase A2 and CoA-independent transacylase)

RN 171103-10-9 CAPLUS

CN Benzoic acid, 2-[2-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB The title compds. [I; R1 = H, cyano, CF3; R2, R4, R5 = H, halo; R3 = halo, CF3, CF3O, CF3SO2; R6 = NR7R8, CH2CHR11CO2R12; R7, R8 = H, alkoxycarbonylethyl, COR9, SO2R10; R9 = (un)substituted alkyl, alkenyl, alkynyl, Ph(CH2), naphthyl, pyridyl, furyl, PhS, alkylamino, etc.; R10 = (un)substituted alkyl, Ph, naphthyl, pyridyl, thienyl; R11 = H, halo; R12 = alkyl] were prepd. as herbicides and plant growth regulators (no data), e.g., by etherification of amino(hydroxy)benzonitriles with halobenzenes. Thus, 3,4,5-trichlorobenzotrifluoride in DMSO was added dropwise to a pre-stirred mixt. of 2-amino-4-hydroxybenzonitrile and NaOH in DMSO and the whole was stirred for 5 h at 50.degree. and 2 h at 90.degree. to give 85% title compd. I (R1 = R5 = Cl, R2 = R4 = H, R3 = CF3, R6 = NH2).
AN 1991:101367 CAPLUS
DN 114:101367
TI Preparation of phenoxybenzonitriles as herbicides and plant growth regulators
IN Busse, Ulrich; Santel, Hans Joachim; Schmidt, Robert R.; Luerssen, Klaus; Strang, Harry
PA Bayer A.-G., Fed. Rep. Ger.
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 379915	A1	19900801	EP 1990-100701	19900113
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	JP 02233655	A2	19900917	JP 1990-11973	19900123
PRAI	DE 1989-3902288		19890126		

OS MARPAT 114:101367
IT **132147-05-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide and plant growth regulator)
RN 132147-05-8 CAPLUS
CN Urea, N-[2-cyano-5-[2,6-dichloro-4-(trifluoromethyl)phenoxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Cl
CN
O
O
NH
C
NH
CF3
F3C
Cl

L5 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2002 ACS

AB Anilines RZC6H4NH2 (R = heteroaryl, e.g., 6-chloro-3-pyridazinyl, Z = O, SO2) were prepd. and converted into their corresponding ureas, carbamates, carboxamides, and benzenesulfonamides by treatment with isocyanates, chloroformates, and acyl halides, resp.

AN 1984:510849 CAPLUS
DN 101:110849

TI Synthesis of potential plant protective agents and pesticides from substituted anilines

AU Kempter, Gerhard; Beerbalk, H. D.
CS Sekt. Chem./Biol., Paedagog. Hochsch. "Karl Liebknecht", Potsdam-Sanssouci, DDR-1500, Ger. Dem. Rep.

SO Wiss. Z. Paedagog. Hochsch. "Karl Liebknecht" Potsdam (1983), 27(1), 101-20
CODEN: WPKLAO; ISSN: 0138-290X
DT Journal
LA German
OS CASREACT 101:110849

IT **91619-55-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 91619-55-5 CAPLUS

CN Urea, N-[4-(3-pyridinyloxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS

AB Chem. structures have been identified which allosterically modify pyruvate kinase and inhibit enzymic activity. These compds. can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, e.g. the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying Hb's oxygen affinity, treatments of tumor and **cancer** and Alzheimer's disease. Prepn. of e.g. 2-phenylethyloxy-5-formylbenzoic acid is described.

AN 2001:869018 CAPLUS

DN 136:700

TI Allosteric inhibitors of pyruvate kinase for therapeutic use

IN Abraham, Donald J.; Wang, Changging; Danso-Danquah, Richmond; Burnett, James C.; Joshi, Gajanan S.; Hoffman, Steven J.

PA USA

SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. 6,214,879. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001046997	A1	20011129	US 2001-799873	20010307
	US 6214879	B1	20010410	US 1998-46643	19980324
PRAI	US 1998-46643	A2	19980324		

IT **289060-07-7**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyruvate kinase allosteric inhibitors for therapeutic use)

RN 289060-07-7 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-(methoxycarbonyl)-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, dimethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS

GI

Print selected from Online session15/07/2002

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; X = O, S; A = 1,4-C6H4, 1,3-C6H4, 1,7-naphthyl; L = H, 2,6-(CH3)2, 2-(CH3)3C, 6-(CH3)3C; R1 = CH3NHCO, CH3CH2NHCO, (CH3)3CNHCO, CH3(CH2)5NHCO, CF3NHCO, C6H5NHCO, 2-CH3C6H4NHCO, 3-CH3C6H4NHCO, 4-CH3C6H4NHCO, 2,6-(CH3)2C6H3NHCO, 4-CF3C6H4NHCO, 2,3-F2C6H4NHCO; q = 0-8; m = 0-8; n = 0-8] and pharmacol. acceptable salts, which are useful as therapeutic and/or preventive agents for diabetes, hyperlipemia, arteriosclerosis, **cancers**, are prepd. Thus, the title compd. II was prepd.

AN 2000:742094 CAPLUS

DN 133:296435

TI Preparation of amine derivatives useful agents for diabetes, hyperlipemia, arteriosclerosis, and **cancer**

IN Fujita, Takashi; Wada, Kunio; Oguchi, Minoru; Honma, Hidehito; Fujiwara, Toshihiko

PA Sankyo Company, Limited, Japan

SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061581	A1	20001019	WO 2000-JP2216	20000406
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2000351779	A2	20001219	JP 2000-104702	20000406
	EP 1167366	A1	20020102	EP 2000-915362	20000406
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 2000009594	A	20020604	BR 2000-9594	20000406
	NO 2001004847	A	20011207	NO 2001-4847	20011005
PRAI	JP 1999-99981	A	19990407		
	WO 2000-JP2216	W	20000406		

OS MARPAT 133:296435

IT **301548-73-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amine derivs. as useful agents for diabetes, hyperlipemia, arteriosclerosis, and **cancer**)

RN 301548-73-2 CAPLUS

CN Urea, N-[3-[[2-[[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenoxy]methyl]-1-methyl-1H-benzimidazol-6-yl]oxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS
GI



II

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS

AB ET-18-O-CH3 (1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine) is an antiproliferative agent, blocking the growth of **cancer** cells both in vitro and in vivo. However, there is controversy regarding the mechanism leading to its antiproliferative effects. CoA-independent transacylase (CoA-IT) is an enzyme that remodels arachidonate between specific phospholipid donor and acceptor mols. in a variety of mammalian cells. ET-18-O-CH3 was a potent inhibitor of CoA-IT (IC50, 0.5 .mu.M), and kinetic anal. revealed that its inhibition was competitive with the lyso-phospholipid substrate. The goal of the current study was to explore the connection between inhibition of CoA-IT and antiproliferative effects using several structurally distinct inhibitors of CoA-IT. ET-18-O-CH3 and other inhibitors of CoA-IT were found to inhibit cell proliferation and thymidine incorporation into the DNA, as well as to induce apoptosis in human HL-60 monocytic leukemia cells. The mechanism of apoptosis induced by ET-18-O-CH3 appeared to be different from that induced by tumor necrosis factor; the former failed to activate NF-.kappa.B, whereas tumor necrosis factor did. Closer examn. of the pharmacol. of apoptosis in this model revealed that compds. that were structurally related to CoA-IT inhibitors, but lacked CoA-IT inhibitory activity, also failed to induce apoptosis. In addn., compds. that inhibited other enzymes that participate in arachidonic acid metab., cyclooxygenase, 5-lipoxygenase and phospholipase A2, did not induce apoptosis. Taken together, these results demonstrate that inhibition of CoA-IT can be linked to blockade of proliferation and the induction of apoptosis in HL-60 cells.

AN 1996:702444 CAPLUS
DN 126:166148

TI Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells

AU Winkler, James D.; Eris, Tamer; Sung, Chiu-Mei; Chabot-Fletcher, Marie; Mayer, Ruth J.; Surette, Marc E.; Chilton, Floyd H.
CS Dep. Immunopharmacol. Med. Chem., SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA

SO Journal of Pharmacology and Experimental Therapeutics (1996), 279(2), 956-966
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English

IT **162793-63-7**, Skf 45905
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors of CoA-independent transacylase induce apoptosis in human HL-60 cells)

RN 162793-63-7 CAPLUS
CN Benzenesulfonic acid, 4,5-dichloro-2-[2-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)


Cl
Cl
O
SO3H
O
NH
C
NH
F3C
Cl
CF3